# Patent

## Title
Compositions and uses thereof

## Abstract

Provided are solid dispersions, solid molecular complexes, salts and crystalline polymorphs involving propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide.

## Background
FIELD OF THE INVENTION
Disclosed are compositions that include compounds, such as biologically active compounds, and methods of making such compositions.
BACKGROUND OF THE INVENTION
PCT Application Publication Number WO 2007/002325 discloses propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide (see e.g., page 80 and corresponding formula on page 82).
SUMMARY OF THE INVENTION
The present inventions provide compositions that include or relate to Compound I. “Compound I” as used herein means propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide (the compound has also been referred to using the nomenclature “propane-1-sulfonic acid {3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-caronyl-2,4-difluoro-phenyl]-amide}”), salts of such compound (including pharmaceutically acceptable salts), conjugates of such compound, derivatives of such compound, forms of such compound , and prodrugs of such compound. The structure of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide is shown as Formula I below.




propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo [2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide
As used herein, the term “solid dispersion” means any solid composition having at least two components. In certain embodiments, a solid dispersion as disclosed herein includes an active ingredient (for example Compound 1); preferably dispersed among at least one other component, for example a polymer. In certain embodiments, a solid dispersion as disclosed herein is a pharmaceutical dispersion that includes at least one pharmaceutically or biologically active ingredient (for example Compound 1). In some embodiments, a solid dispersion includes Compound I molecularly dispersed with a polymer. Preferably the solid dispersion exists as a one phase system. An especially preferred solid dispersion according to the present invention is microprecipitated bulk powder (MBP) comprising Compound I.
The term “molecularly dispersed”, as used herein, refers to the random distribution of a compound (e.g., Compound I) with a polymer. In certain embodiments the compound is present in the polymer in a final state of subdivision. See, e.g., M. G. Vachon et al., J. Microencapsulation, 14:281-301 (1997) and Vandelli et al., J. Microencapsulation, 10: 55-65 (1993). In some embodiments, a compound (for example, Compound I) may be dispersed within a matrix formed by the polymer in its solid state such that the compound is immobilized in its amorphous form. Whether a compound is molecularly dispersed in a polymer may be evidenced in a variety of ways, e.g., by the resulting solid molecular complex having a single glass transition temperature.
The term “solid molecular complex” as used herein means a solid dispersion that includes Compound I molecularly dispersed within a polymer matrix.
The term “immobilize”, as used herein with reference to the immobilization of the active compound in the polymer matrix, means that molecules of the compound interact with molecules of the polymer in such a way that the molecules of the compound are held in the aforementioned matrix and prevented from crystal nucleation due to lack of mobility. In some embodiments the polymer may prevent intermolecular hydrogen bonding or weak dispersion forces between two or more drug molecules of Compound I. See, for example, Matsumoro and Zografi, Pharmaceutical Research, Vo. 16, No. 11, p 1722-1728, 1999.
Accordingly, in a first aspect, provided is a solid dispersion that includes Compound I and a polymer. Also provided is a solid molecular complex that includes Compound I and a polymer. The polymer may be a non-ionic polymer or an ionic polymer. In certain embodiments, the polymer is selected from the group consisting of hydroxypropylmethyl cellulose acetate succinate, hydroxypropylmethyl cellulose, methacrylic acid copolymers, and the like, as well as mixtures of any two or more thereof. In some embodiments the ratio of the amount by weight of Compound I within the solid dispersion or solid molecular complex to the amount by weight of the ionic polymer therein is from about 1:9 to about 5:5. In a preferred embodiment of the invention, the ratio of the amount by weight of Compound I within the solid dispersion or solid molecular complex to the amount by weight of the ionic polymer therein is from about 2:8 to about 4:6. In various embodiments the ratio of Compound Ito the polymer in the solid dispersion is not 1:1; for example the ratio may be about 2:8; or about 3:7; or about 4:6. In a preferred embodiment, the ratio of the amount by weight of Compound I within the solid dispersion or solid molecular complex to the amount by weight of the ionic polymer therein is about 3:7. In certain preferred embodiments Compound I may be present in the solid dispersion in an amount of from about 0.1% to about 80%, by weight, of the solid dispersion; or in amount of from about 10% to about 70%, by weight, of the solid dispersion; or in an amount of from about 20% to about 60%, by weight, of the solid dispersion; or in an amount of from about 20% to about 40%, by weight, of the solid dispersion; or in an amount of about 30%, by weight, of the solid dispersion. In certain embodiments of the solid dispersions, the polymer may be present in the solid dispersion in an amount of not less than about 20%, by weight, of the solid dispersion; or in an amount of from about 20% to about 95% by weight of the solid dispersion; or in an amount of from about 20% to about 70% by weight of the solid dispersion.
In certain preferred embodiments Compound I is stable in the solid dispersion (or solid molecular complex) for at least 2 months at 25° C.; or for at least 6 months at 25° C.; or for at least 12 months at 25° C.; or for at least 15 months at 25° C.; or for at least 18 months at 25° C.; or for at least 24 months at 25° C.; or for at least 2 months at 40° C. and 75% relative humidity; or for at least 4 months at 40° C. and 75% relative humidity; or for at least 5 months at 40° C. and 75% relative humidity; or for at least 6 months at 40° C. and 75% relative humidity. In certain preferred embodiments, Compound I is immobilized so that it is primarily in amorphous form within the solid dispersion or solid molecular complex for at least three weeks of storage at 40° C. and 75% relative humidity; or for at least one month of storage at 40° C. and 75% relative humidity; or for at least two months of storage at 40° C. and 75% relative humidity; or for at least three months of storage at 40° C. and 75% relative humidity; or for at least four months of storage at 40° C. and 75% relative humidity; or for at least five months of storage at 40° C. and 75% relative humidity; or for at least six months of storage at 40° C. and 75% relative humidity.
In some embodiments, Compound I is present in the complex as a tosylate salt; or as a mesylate salt. The complex may further include a pharmaceutically acceptable carrier.
As used herein, the term “primarily in amorphous form” means that greater than 50%; or greater than 55%; or greater than 60%; or greater than 65%; or greater than 70%; or greater than 75%; or greater than 80%; or greater than 85%; or greater than 90%; or greater than 95% of the compound present in a composition is in amorphous form.
As used herein, the term “about” used in the context of quantitative measurements means the indicated amount ±10%. For example, “about 2:8” would mean 1.8-2.2:7.2-8.8.
As used herein in the context of a pharmaceutically or biologically active compound (for example Compound I), the term “stable” refers to the ability of the compound to retain its activity or to retain certain physical or chemical properties under certain specified conditions. In some embodiments, an active compound is “stable” if the activity at the end of the specified period is at least 50%; or at least 60%; or at least 70%; or at least 75%; or at least 80%; or at least 85%; or at least 90%; or at least 95%; or at least 98% of the activity of the compound at the beginning of the specified period. In some embodiments, a compound in an amorphous form is stable if at least 50%; or at least 60%; or at least 70%; or at least 75%; or at least 80%; or at least 85%; or at least 90%; or at least 95%; or at least 98% of the compound remains in the amorphous form at the end of the specified period. In further embodiments, an amorphous compound is stable if it does not form any detectable crystalline peaks in powder XRD profiles during the indicated period.
The term “methacrylic acid copolymers” as used herein includes methacrylic acid copolymers, methacrylic acid-methacrylate copolymers, methacrylic acid-ethyl acrylate copolymers, ammonium methacrylate copolymers, aminoalkyl methacrylate copolymers and the like. In certain embodiments, a “methacrylic acid copolymer” may be EUDRAGIT® L 100 and EUDRAGIT® L 12,5 (also referred to as, or conforms with: “Methacrylic Acid Copolymer, Type A;” “Methacrylic Acid-Methyl Methacrylate Copolymer (1:1);” “Methacrylic Acid Copolymer L;” “DMF 1242” or “PR-MF 6918”); EUDRAGIT® S 100 and EUDRAGIT® S 12,5 (also referred to as, or conforms with: “Methacrylic Acid Copolymer, Type B;” “Methacrylic Acid-Methyl Methacrylate Copolymer (1:2);” “Methacrylic Acid Copolymer S;” “DMF 1242” or “PR-MF 6918”); EUDRAGIT® L 100-55 (also referred to as, or conforms with: “Methacrylic Acid Copolymer, Type C;” “Methacrylic Acid-Ethyl Acrylate Copolymer (1:1) Type A;” “Dried Methacrylic Acid Copolymer LD;” or “DMF 2584”); EUDRAGIT® L 30 D-55 (also referred to as, or conforms with: “Methacrylic Acid Copolymer Dispersion;” “Methacrylic Acid-Ethyl Acrylate Copolymer (1:1) Dispersion 30 Percent;” “Methacrylic Acid Copolymer LD;” JPE DMF 2584; PR-MF 8216); EUDRAGIT® FS 30 D (also referred to as DMF 13941 or DMF 2006-176); EUDRAGIT® RL 100 (also referred to as, or conforms with: “Ammonio Methacrylate Copolymer, Type A;” “Ammonio Methacrylate Copolymer (Type A);” “Aminoalkyl Methacrylate Copolymer RS;” “DMF 1242” or “PR-MF 6918”); EUDRAGIT® RL PO (also referred to as, or conforms with: “Ammonio Methacrylate Copolymer, Type A;” “Ammonio Methacrylate Copolymer (Type A);” “Aminoalkyl Methacrylate Copolymer RS;” “DMF 1242”); EUDRAGIT® RL 12,5 (also referred to as, or conforms with “Ammonio Methacrylate Copolymer, Type A;” “Ammonio Methacrylate Copolymer (Type A);” “DMF 1242” or “PR-MF 6918”); EUDRAGIT® L 100-55 (also referred to as, or conforms with: “Methacrylic Acid Copolymer, Type C;” “Methacrylic Acid-Ethyl Acrylate Copolymer (1:1) Type A;” “Dried Methacrylic Acid Copolymer LD;” “DMF 2584”); EUDRAGIT® L 30 D-55 (also referred to as, or conforms with: “Methacrylic Acid Copolymer Dispersion” NF “Methacrylic Acid-Ethyl Acrylate Copolymer (1:1) Dispersion 30 Percent;” “Methacrylic Acid Copolymer LD;” “DMF 2584” or “PR-MF 8216”); EUDRAGIT® FS 30 D (also referred to as, or conforms with: “DMF 13941” or “DMF 2006-176”); EUDRAGIT® RL 100 (also referred to as, or conforms with: “Ammonio Methacrylate Copolymer, Type A;” “Ammonio Methacrylate Copolymer (Type A);” “Aminoalkyl Methacrylate Copolymer RS;” “DMF 1242;” or “PR-MF 6918”); EUDRAGIT® RL PO (also referred to as, or conforms with: “Ammonio Methacrylate Copolymer, Type A;” “Ammonio Methacrylate Copolymer (Type A);” “Aminoalkyl Methacrylate Copolymer RS;” or “DMF 1242”); EUDRAGIT® RL 12,5 (also referred to as, or conforms with: polymer conforms to “Ammonio Methacrylate Copolymer, Type A;” “Ammonio Methacrylate Copolymer (Type A);” “DMF 1242” or “PR-MF 6918”); EUDRAGIT® RL 30 D (also referred to as, or conforms with: “Ammonio Methacrylate Copolymer Dispersion, Type A;” “Ammonio Methacrylate Copolymer (Type A);” or “DMF 1242”); EUDRAGIT® RS 100 (also referred to as, or conforms with: “Ammonio Methacrylate Copolymer, Type B;” NF “Ammonio Methacrylate Copolymer (Type B);” “Aminoalkyl Methacrylate Copolymer RS;” “DMF 1242” or “PR-MF 6918”); EUDRAGIT® RS PO (also referred to as, or conforms with: “Ammonio Methacrylate Copolymer, Type B;” “Ammonio Methacrylate Copolymer (Type B);” “Aminoalkyl Methacrylate Copolymer RS;” or “DMF 1242”); EUDRAGIT® RS 12,5 (also referred to as, or conforms with: “Ammonio Methacrylate Copolymer, Type B;” NF polymer conforms to “Ammonio Methacrylate Copolymer (Type B);” “DMF 1242” or “PR-MF 6918”); EUDRAGIT® RS 30 D (also referred to as, or conforms with: “Ammonio Methacrylate Copolymer Dispersion, Type B;” NF polymer conforms to “Ammonio Methacrylate Copolymer (Type B);” or “DMF 1242”); EUDRAGIT® E 100 (also referred to as, or conforms with: “Amino Methacrylate Copolymer;” NF “Basic Butylated Methacrylate Copolymer;” “Aminoalkyl Methacrylate Copolymer E;” “DMF 1242” or “PR-MF 6918”); EUDRAGIT® E PO (also referred to as, or conforms with: “Basic Butylated Methacrylate Copolymer;” “Aminoalkyl Methacrylate Copolymer E;” “Amino Methacrylate Copolymer;” “DMF 1242”); EUDRAGIT® E 12,5 (also referred to as, or conforms with: “Amino Methacrylate Copolymer;” “Basic Butylated Methacrylate Copolymer;” “DMF 1242” or “PR-MF 6918”); EUDRAGIT® NE 30 D (also referred to as, or conforms with: “Ethyl Acrylate and Methyl Methacrylate Copolymer Dispersion;” “Polyacrylate Dispersion 30 Percent;” (“Poly(ethylacrylat-methylmethacrylat)-Dispersion 30%”); “Ethyl Acrylate Methyl Methacrylate Copolymer Dispersion;” “DMF 2822” or “PR-MF 6918”); EUDRAGIT® NE 40 D (also referred to as, or conforms with: DMF 2822); EUDRAGIT® NM 30 D (also referred to as “Polyacrylate Dispersion 30 Percent;” “(Poly(ethylacrylat-methylmethacrylat)-Dispersion 30%);” or “DMF 2822”; PLASTOID® B (also referred to as, or conforms with: “DMF 12102”), or the like.
In a second aspect, provided are methods of making solid dispersions or solid molecular complexes as disclosed herein. The method may involve using Compound. I in the form of a tosylate or mesylate salt.
In a third aspect, provided is a crystalline polymorph Form 1 of Compound I. In certain embodiments the crystalline polymorph Form 1 of Compound I exhibits a powder x-ray diffraction pattern having characteristic peak locations of approximately 4.7, 9.4, 11.0, 12.5, and 15.4 degrees 2θ; or having characteristic peak locations of approximately 4.7, 9.4, 10.0, 11.0, 12.5, 14.2, 15.4, 18.6, and 22.2 degrees 2θ; or having characteristic peak locations of approximately 4.7, 9.4, 10.0, 11.0, 12.5, 14.2, 15.4, 16.1, 18.6, 19.0, 22.2 and 26.8 degrees 2θ. In certain embodiments the crystalline polymorph Form 1 of Compound I exhibits a powder x-ray diffraction pattern substantially the same as the powder x-ray diffraction pattern of FIG. 1. Also provided are methods of preparing solid dispersions and solid molecular complexes as described herein wherein the solid dispersion or solid molecular complex is prepared from Compound I in the form of crystalline polymorph Form 1.
In a fourth aspect, provided is a crystalline polymorph Form 2 of Compound I. In certain embodiments the crystalline polymorph Form 2 of Compound I exhibits a powder x-ray diffraction pattern having characteristic peak locations of approximately 8.8, 9.2, 13.5, 19.1 and 24.4 degrees 2θ; or having characteristic peak locations of approximately 6.7, 8.8, 9.2, 13.5, 15.0, 17.7, 19.1, 19.7, 21.4 and 24.4 degrees 2θ; or having characteristic peak locations of approximately 6.7, 8.8, 9.2, 13.5, 14.1, 14.5, 15.0, 16.2, 17.0, 17.7, 19.1, 19.7, 21.4, 22.2, 24.1, 24.4, and 28.1 degrees 2θ. In certain embodiments the crystalline polymorph Form 2 of Compound I exhibits a powder x-ray diffraction pattern substantially the same as the powder x-ray diffraction pattern of FIG. 2. Also provided are methods of preparing solid dispersions and solid molecular complexes as described herein wherein the solid dispersion or solid molecular complex is prepared from Compound I in the form of crystalline polymorph Form 2.
All atoms within the compound described herein are intended to include any isotope thereof, unless clearly indicated to the contrary. It is understood that for any given atom, the isotopes may be present essentially in ratios according to their natural occurrence, or one or more particular atoms may be enhanced with respect to one or more isotopes using synthetic methods known to one skilled in the art. Thus, hydrogen includes for example 1H, 2H, 3H; carbon includes for example 11C, 12C, 13C, 14C; oxygen includes for example 16O, 17O, 18O; nitrogen includes for example 13N, 14N, 15N; sulfur includes for example 32S, 33S, 34S, 35S, 36S, 37S, 38S; fluoro includes for example 17F, 18F, 19F; chloro includes for example 35Cl, 36Cl, 37Cl, 38Cl, 39Cl; and the like.
As used herein, the term “solid form” refers to a solid preparation (i.e. a preparation that is neither gas nor liquid) of a pharmaceutically active compound that is suitable for administration to an intended animal subject for therapeutic purposes. The solid form includes any complex, such as a salt, co-crystal or an amorphous complex, as well as any polymorph of the compound. The solid form may be substantially crystalline, semi-crystalline or substantially amorphous. The solid form may be administered directly or used in the preparation of a suitable composition having improved pharmaceutical properties. For example, the solid form may be used in a formulation comprising at least one pharmaceutically acceptable carrier or excipient.
As used herein, the term “substantially crystalline” material embraces material which has greater than about 90% crystallinity; and “crystalline” material embraces material which has greater than about 98% crystallinity.
As used herein, the term “substantially amorphous” material embraces material which has no more than about 10% crystallinity; and “amorphous” material embraces material which has no more than about 2% crystallinity.
As used herein, the term “semi-crystalline” material embraces material which is greater than 10% crystallinity, but no greater than 90% crystallinity; preferably “semi-crystalline” material embraces material which is greater than 20% crystallinity, but no greater than 80% crystallinity. In one aspect of the present invention, a mixture of solid forms of a compound may be prepared, for example, a mixture of amorphous and crystalline solid forms, e.g. to provide a “semi-crystalline” solid form. Such a “semi-crystalline” solid form may be prepared by methods known in the art, for example by mixing an amorphous solid form with a crystalline solid form in the desired ratio. In some instances, a compound mixed with acid or base forms an amorphous complex; a semi-crystalline solid can be prepared employing an amount of compound component in excess of the stoichiometry of the compound and acid or base in the amorphous complex, thereby resulting in an amount of the amorphous complex that is based on the stoichiometry thereof, with excess compound in a crystalline form. The amount of excess compound used in the preparation of the complex can be adjusted to provide the desired ratio of amorphous complex to crystalline compound in the resulting mixture of solid forms. For example, where the amorphous complex of acid or base and compound has a 1:1 stoichiometry, preparing said complex with a 2:1 mole ratio of compound to acid or base will result in a solid form of 50% amorphous complex and 50% crystalline compound. Such a mixture of solid forms may be beneficial as a drug product, for example, by providing an amorphous component having improved biopharmaceutical properties along with the crystalline component. The amorphous component would be more readily bioavailable while the crystalline component would have a delayed bioavailability. Such a mixture may provide both rapid and extended exposure to the active compound.
As used herein, the term “complex” refers to a combination of a pharmaceutically active compound and an additional molecular species that forms or produces a new chemical species in a solid form. In some instances, the complex may be a salt, i.e. where the additional molecular species provides an acid/base counter ion to an acid/base group of the compound resulting in an acid:base interaction that forms a typical salt. While such salt forms are typically substantially crystalline, they can also be partially crystalline, substantially amorphous, or amorphous forms. In some instances, the additional molecular species, in combination with the pharmaceutically active compound, forms a non-salt co-crystal, i.e. the compound and molecular species do not interact by way of a typical acid:base interaction, but still form a substantially crystalline structure. Co-crystals may also be formed from a salt of the compound and an additional molecular species. In some instances, the complex is a substantially amorphous complex, which may contain salt-like acid:base interactions that do not form typical salt crystals, but instead form a substantially amorphous solid, i.e. a solid whose X-ray powder diffraction pattern exhibits no sharp peaks (e.g. exhibits an amorphous halo).
As used herein, the term “stoichiometry” refers to the molar ratio of two or more reactants that combine to form a complex, for example, the molar ratio of acid or base to compound that form an amorphous complex. For example, a 1:1 mixture of acid or base with compound (i.e. 1 mole acid or base per mole of compound) resulting in an amorphous solid form has a 1:1 stoichiometry.
As used herein, the term “composition” refers to a pharmaceutical preparation suitable for administration to an intended animal subject for therapeutic purposes that contains at least one pharmaceutically active compound, including any solid form thereof. The composition may include at least one additional pharmaceutically acceptable component to provide an improved formulation of the compound, such as a suitable carrier or excipient.
The term “pharmaceutically acceptable” indicates that the indicated material does not have properties that would cause a reasonably prudent medical practitioner to avoid administration of the material to a patient, taking into consideration the disease or conditions to be treated and the respective route of administration. For example, it is commonly required that such a material be essentially sterile, e.g., for injectibles.
In the present context, the term “therapeutically effective” or “effective amount” indicates that the materials or amount of material is effective to prevent, alleviate, or ameliorate one or more symptoms of a disease or medical condition, and/or to prolong the survival of the subject being treated. In certain embodiments, a “therapeutically-effective amount” of Compound I refers to such dosages and/or administration for such periods of time necessary to inhibit human b-Raf containing the V600E mutation. Moreover, a therapeutically effective amount may be one in which the overall therapeutically-beneficial effects outweigh the toxic or undesirable side effects. A therapeutically-effective amount of Compound I may varies according to disease state, age and weight of the subject being treated. Thus, dosage regimens are typically adjusted to the individual requirements in each particular case and are within the skill in the art. In certain embodiments, an appropriate daily dose for administration of Compound I to an adult human may be from about 100 mg to about 3200 mg; or from about 250 mg to about 2000 mg, although the upper limit may be exceeded when indicated. A daily dosage of Compound I can be administered as a single dose, in divided doses, or, for parenteral administration, it may be given as subcutaneous injection.
In the present context, the terms “synergistically effective” or “synergistic effect” indicate that two or more compounds that are therapeutically effective, when used in combination, provide improved therapeutic effects greater than the additive effect that would be expected based on the effect of each compound used by itself.
As used herein, the term “modulating” or “modulate” refers to an effect of altering a biological activity, especially a biological activity associated with a particular biomolecule such as a protein kinase. For example, an agonist or antagonist of a particular biomolecule modulates the activity of that biomolecule, e.g., an enzyme, by either increasing (e.g. agonist, activator), or decreasing (e.g. antagonist, inhibitor) the activity of the biomolecule, such as an enzyme. Such activity is typically indicated in terms of an inhibitory concentration (IC50) or excitation concentration (EC50) of the compound for an inhibitor or activator, respectively, with respect to, for example, an enzyme.
Additional aspects and embodiments will be apparent from the following Detailed Description and from the claims.



BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a powder x-ray diffraction pattern for the crystalline polymorph Form 1 of Compound I.
FIG. 2 is a powder x-ray diffraction pattern for the crystalline polymorph Form 2 of Compound I.
FIG. 3 is a comparison of powder x-ray diffraction pattern for the crystalline polymorph Form 2 and the mesylate salt of Compound I.
FIG. 4 is a comparison of powder x-ray diffraction pattern for the crystalline polymorph Form 2 and the tosylate salt of Compound I.
FIG. 5 is a schematic drawing of an exemplary setup for manufacturing a solid dispersion (MBP) according to steps a) to d), more specifically according to Example 22 of the present invention.
FIG. 6 is a detailed schematic drawing of the high shear mixing unit ((6) of FIG. 5).
FIGS. 7A and 7B provide a comparison of X-ray patterns obtained from two lots of solid dispersions (MBP's) containing HPMCAS and Compound I, manufactured via high shear mixer precipitation according to the method disclosed in Example 22 (see FIG. 7A) and via conventional spray precipitation (see FIG. 7B).



DETAILED DESCRIPTION
Propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo [2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide, is a compound with the following structure:




Propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo [2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl} -amide (Compound I)
In some embodiments, Compound I is a b-raf kinase inhibitor. Normally functioning b-Raf is a kinase which is involved in the relay of signals from the cell membrane to the nucleus and is active only when it is needed to relay such signals. Mutant b-Raf, however, is constantly active and thus plays a role in tumor development. Mutant b-Raf containing a V600E mutation has been implicated in various tumors, for example, colorectal cancer, melanoma, and thyroid cancer. Propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide specifically targets mutant b-Raf containing the V600E mutation. Accordingly, such an inhibitor is used in the inhibition of tumors, particularly solid tumors such as melanoma. As previously stated, the phrase “Compound I”, as used herein, will refer to propane-1-sulfonic acid {3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl-2,4-difluoro-phenyl]-amide as well as any salt, conjugate, derivative, or prodrug thereof.
Compounds that have low solubility in water (for example, certain compounds in crystalline form), have a low dissolution rate and as a result can exhibit poor bioavailability. Poorly bioavailable compounds can present problems for therapeutic administration to a patient, often due to unpredictability in dose/therapy effects caused by erratic absorption of the compound by the patient. For example, the intake of food may affect the ability of the patient to absorb such poorly bioavailable compounds, thus potentially requiring dosing regimens to take into account the effect of food. In addition, when dosing, a large safety margin may be required for the dose as a result of the unpredictable dose effects. Further, due to poor bioavailability, a large dose of the compound may be required to achieve a desired therapeutic effect, thus potentially resulting in undesired side effects.
Amorphous forms of Compound I have improved solubility in water as compared to the crystalline form, but is unstable as it has a tendency to crystallize. Thus it is desired to formulate Compound I so that it may stably exist primarily in amorphous form.
Thus, in some aspects and embodiments disclosed and described herein, techniques, methods and compositions for improving the solubility and/or bioavailability of Compound I are provided. In certain embodiments, provided are compositions and methods involving Compound I in a composition, form, or formulation in which it has improved water solubility and/or bioavailability of as compared to Compound I in a crystalline form, or Compound I in a primarily crystalline form.
In some embodiments provided are compositions including Compound I in an amorphous form of the compound. The amorphous form of Compound I may have improved solubility in water as compared to Compound I in a crystalline form. In certain embodiments, formulations of Compound I in which Compound I exists stably in amorphous form may be accomplished, for example, by immobilizing the compound within a matrix formed by a polymer. See, for example, U.S. Pat. No. 6,350,786.
Solid Dispersions and Solid Molecular Complexes of Compound I and a Polymer
In some aspects and embodiments provided are solid dispersions and solid molecular complexes that include Compound I. For example, Compound I may be dispersed within a matrix formed by a polymer in its solid state such that it is immobilized in its amorphous form. In some embodiments the polymer may prevent intramolecular hydrogen bonding or weak dispersion forces between two or more drug molecules of Compound I. See, for example, Matsumoro and Zografi, Pharmaceutical Research, Vo. 16, No. 11, p 1722-1728, 1999. In certain embodiments, the solid dispersion provides for a large surface area, thus further allowing for improved dissolution and bioavailability of Compound I. In certain embodiments a solid dispersion or solid molecular complex includes a therapeutically-effective amount of Compound I.
In some embodiments of the present inventions, Compound I is present in the solid dispersion in an amount of from about 1% to about 50%, by weight; or from about 10% to about 40% by weight; or from about 20% to about 35% by weight; or from about 25% to about 30% by weight. In related embodiments, a polymer is present in the solid dispersion in an amount of from about 0% to about 50% by weight; or from about 5% to about 60% by weight; or from 10% to about 70% by weight. In certain embodiments a polymer is present in the solid dispersion in an amount greater than about 10% by weight; or greater than about 20% by weight; or greater than about 30% by weight; or greater than about 40% by weight; or greater than about 50% by weight. In one preferred embodiment, the solid dispersion is about 30% by weight Compound I and about 70% by weight polymer.
The solid dispersion may comprise Compound I dispersed in a non-ionic polymer. This may be accomplished by various means, including: (A) melting the polymer and dissolving the compound in the polymer and then cooling the mixture; and (B) dissolving both the compound of interest and the polymer in an organic solvent and evaporating the solvent in a rotary evaporator, for example. The resulting solid dispersion may comprise the compound dispersed in the polymer in amorphous form.
A solid dispersion may be formed by dispersing Compound I in an ionic polymer. Such solid dispersion may result in increased stability of Compound I. This may be accomplished by various means, including the methods described above for use in forming a dispersion in a non-ionic polymer. Because ionic polymers have pH dependent solubility in aqueous systems, the resulting solid dispersion of the Compound I and the polymer may be stable at low pH in the stomach and release the Compound I in the intestine at higher pH which is the site of absorption. In preferred embodiments, Compound I in such solid dispersions with an ionic polymer may thus be less capable of separating from the polymer and may be immobilized by the polymer in its amorphous form. Any ionic polymer may be used in the practice of the present invention. Examples of such ionic polymers include hydroxypropylmethyl cellulose acetate succinate (HPMC-AS), hydroxypropylmethyl cellulose phthalate (HPMCP), and methacrylic acid copolymers. Because one purpose of formulating Compound I in a complex with an ionic polymer is to allow for Compound Ito be immobilized so that it exists primarily in amorphous form, a polymer which is capable of immobilizing Compound I so that it exists primarily in an amorphous form for an extended period of time is preferred. It has been found that polymers such as HPMC-AS and Eudragit® L 100-55 (a methacrylic acid copolymer) are capable of immobilizing Compound I so that it exists primarily in an amorphous form for at least four weeks while in storage at 40° C. and 75% relative humidity. As such, HPMC-AS and Eudragit® L 100-55 are preferred polymers for use in certain embodiments of the present invention.
HPMC-AS (HPMCAS or AQOATTM, which is available from, for example, Shin-Etsu) is a particularly preferred polymer for use in the practice of certain embodiments of the present invention. It is available in the following grades: AS-LF, AS-MF, AS-HF, AS-LG, AS-MG and AS-HG. HPMC-AS is an anionic, relatively water insoluble, high molecular weight polymer with a pH dependent water solubility, leading to dissolution at pH 5.2 and above. Said dissolution can be tailored between pH 5.2 and 6.5 according to the HPMC-AS grades used. HPMC-AS may be relatively resistant to breakdown in the acidic environment of the stomach and under normal temperatures of storage. At the same time, because HPMC-AS dissolves at pH 5.2 and above, it dissolves in the basic environment of the intestine, thus allowing for improved absorption of Compound I and further allowing for improved bioavailability of the Compound I. Accordingly, in certain embodiments of the invention, Compound I is in a solid dispersion with at least one polymer selected from HPMC-AS grades as mentioned above. It is, however, contemplated that a mixture of two or more of the various HPMC-AS grades can also be used in accordance with the present invention.
In an embodiment of the invention, the ratio of the amount by weight of Compound I within the solid complex to the amount by weight of the ionic polymer therein is from about 1:9 to about 1:1. In a preferred embodiment of the invention, the ratio of the amount by weight of Compound I within the solid complex to the amount by weight of the ionic polymer therein is from about 2:8 to about 4:6. In a preferred embodiment of the invention, the ratio of the amount by weight of Compound I within the solid complex to the amount by weight of the ionic polymer therein is about 3:7.
In an embodiment of the present invention, Compound I is immobilized so that it is primarily in amorphous form within the complex for up to three weeks of storage at 40° C. and 75% relative humidity. In a preferred embodiment, Compound I is immobilized so that it is primarily in amorphous form within the complex for up to one month of storage at 40° C. and 75% relative humidity. In another preferred embodiment, Compound I is immobilized so that it is primarily in amorphous form within the complex for up to two months of storage at 40° C. and 75% relative humidity. In another preferred embodiment, Compound I is immobilized so that it is primarily in amorphous form within the complex for up to three months of storage at 40° C. and 75% relative humidity.
In certain embodiments, HPMC-AS is present in the solid dispersion in amount of from about 1% to about 50% by weight; or from about 5% to about 60% by weight; or from 10% to about 70% by weight. In certain embodiments, HPMC-AS is present in the solid dispersion in an amount greater than about 10% by weight; or greater than about 20% by weight or greater than about 30% by weight; or greater than about 40% by weight; or greater than about 50% by weight.
The present inventions also relate to compositions comprising a solid dispersion or solid molecular complex as disclosed herein. The composition may, in addition to the solid dispersion or solid molecular complex, also comprise therapeutically inert, inorganic or organic carriers (for example, pharmaceutically-acceptable carriers or excipients). The pharmaceutical composition may also contain additional agents such as preserving agents, solubilizing agents, stabilizing agents, wetting agents, emulsifying agents, sweetening agents, coloring agents, flavoring agents, salts for varying the osmotic pressure, buffers, coating agents and antioxidants. The composition may also contain additional therapeutically-active compounds or more than one therapeutically-active compound/polymer complex (e.g., a solid dispersion or solid molecular complex).
In certain embodiments, the composition includes the solid dispersion or solid molecular complex suspended in an aqueous vehicle containing hydroxypropylcellulose (HPC). In an especially preferred embodiment, the vehicle contains about 2% by weight HPC. In a preferred embodiment, the composition includes colloidal silicon dioxide (silica).
In certain embodiments, the addition of colloidal silicon dioxide may further improve the stability of the solid dispersion or solid molecular complex. In an especially preferred embodiment, the composition includes at least about 0.5% by weight colloidal silicon dioxide.
In certain embodiments provided compositions include Compound I (for example in a solid dispersion or solid molecular complex) and Crospovidone (or Polyplasdone XL; a disintegrating agent for the dosage form), magnesium stearate (a lubricant that may be used in tablet and capsulation operations), and/or croscarmellose sodium (AcDiSol; a disintegrating agent).
In an especially preferred embodiment, the composition comprises the solid dispersion or solid molecular complex suspended in an aqueous vehicle that is up to 2% by weight HPC and at least about 0.5% by weight colloidal silicon dioxide.
Method of Making a Solid Molecular Complex of Compound I and an Ionic Polymer
Also provided are methods of making solid molecular complexes as disclosed herein and compositions comprising the solid molecular complexes. In the method, Compound I may be microprecipitated with a polymer as disclosed herein (for example, HPMC-AS). Microprecipitation may be accomplished by any means known in the art, for example: spray drying or lyophilization; solvent-controlled precipitation; pH-controlled precipitation; hot melt extrusion; and supercritical fluid technology. Each of these methods is described in more detail below.
Once the solid dispersion precipitates out of solution using the various methods, it can be recovered from the solution by procedures known to those skilled in the art, for example by filtration, centrifugation, washing, etc. The recovered solid molecular complex can then be dried (e.g., in air, an oven, or a vacuum) and the resulting solid can be milled, pulverized or micronized to a fine powder by means known in the art. The powder form of the solid dispersion can then be dispersed in a carrier to form a pharmaceutical composition. In a preferred embodiment, at least about 0.5% w/w colloidal silicon dioxide is added to the composition.
a) Spray Drying or Lyophilization Process
Compound I and a polymer (for example, HPMC-AS) may be dissolved in a common solvent having a low boiling point, e.g., ethanol, methanol, acetone, etc. By means of spray drying or lyophilization, the solvent is evaporated by flash evaporation at a temperature close to the boiling point thereof, or under a high vacuum (low vapor pressure), leaving Compound I precipitated in a matrix formed by the polymer. In certain embodiments Compound I is in a mesylate or tosylate salt form, and thus preferably has improved solubility.
b) Solvent Controlled Precipitation
Compound I and a polymer (for example, HPMC-AS) may be dissolved in a common solvent, e.g., dimethylacetamide, dimethylformamide, dimethyl sulfoxide (DMSO), N-methyl pyrrolidone (NMP), etc. The Compound I/polymer solution is added to cold (0 to 7° C., preferably 2 to 5° C.) water adjusted to an appropriate pH (for example in many embodiments an appropriate pH is a pH of 3 or less). This causes Compound Ito microprecipitate in a matrix formed by the polymer (for example, HPMC-AS). The microprecipitate may be washed several times with aqueous medium until the residual solvent falls below an acceptable limit for that solvent. An “acceptable limit” for each solvent is determined pursuant to the International Conference on Harmonization (ICH) guidelines.
In a preferred embodiment, a solution comprising Compound I, an organic solvent (such as dimethylformamide, dimethylacetamide (DMA), dimethyl sulfoxide (DMSO), N-methyl pyrrolidone (NMP), and the like) and the ionic polymer is formed. The organic solvent is preferably DMA at 20 to 25° C. The solution may be formed by first dissolving Compound I into the organic solvent. Then, while stirring, the polymer is added. The mixture is then heated up to between about 50 to about 110° C., preferably to about 70° C.
A second solution that is 0.01 N HCl is also formed. This will herein be termed the “aqueous phase”. The aqueous phase has a temperature between about 0 and about 60° C., preferably between 5 and 15° C.
The aqueous phase is then circulated through the mixing chamber of a high shear mixer while the organic phase is dosed into the chamber while the chamber is operating. Dosing may be accomplished with, for example, a gear pump, a hose pump, or a syringe pump. In a preferred embodiment, dosing is accomplished using a gear pump with an injector nozzle pointed into the mixing chamber. The mixing chamber preferably comprises a rotor and a stator. The rotor and the stator may, for example, each have either one or two rows of teeth. In a preferred embodiment, the rotor and the stator each have one row of teeth. The tip speed of the rotor is preferably set at between about 15 and about 25 m/sec.
During the mixing process, Compound I and the polymer precipitate, producing a suspension of particles of the complex of Compound I and the polymer in aqueous organic media. The suspension may then be subjected to a number of passes through a dispersing unit in order to adjust the particle size of the particles of the compound. The suspension may then be centrifuged and washed with the aqueous phase several times in order to remove the organic solvent and then washed once with pure water. The obtained product may then be delumped and dried to obtain the solid complex of the present invention. During the drying process, the temperature of the complex is preferably below 40° C. in order to avoid recrystallization of Compound I.
In certain more specific embodiments, the above method includes the following steps,

    
    
        (a) dissolution of Compound I and HPMCAS in the same organic solvent to give one single organic phase;
        (b) continuously adding the organic phase obtained under (a) into an aqueous phase which is present in a mixing chamber, said mixing chamber being equipped with a high shear mixing unit and two additional openings which connect said mixing chamber to a closed loop wherein said aqueous phase is circulated and passes through the mixing chamber;
        (c) precipitation of a mixture consisting of the amorphous form of Compound I and HPMCAS from the aqueous phase mentioned under (b), while the high shear mixer is operating and said aqueous phase is passed through the mixing chamber in a closed loop, resulting in the formation of an aqueous suspension of the precipitate;
        (d) continuously circulating the aqueous suspension through the mixing chamber while the high shear mixing unit is operating and after the organic solution prepared under (a) has been completely added to the aqueous phase until a defined particle size and/or particle size distribution is obtained;
        (e) isolating the solid phase from the suspension;
        (f) washing the isolated solid phase with water; and
        (g) delumping and drying the solid phase.
    
    


In still more specific embodiments the present methods include the steps, wherein

    
    
        the organic phase in step (a) above is a 35% solution of Compound I and HPMCAS in DMA, the ratio of Compound Ito HPMCAS being 30% to 70% (w/w); and
        the continuous adding in step (b) above is achieved via an injector nozzle which is oriented at an angle between 40 and 50° to the longitudinal axis of the high shear mixer and has a distance of about 1 to about 10 mm from the rotor of said high shear mixer which is operating with a tip speed of about 15 to about 25 msec.
    
    


In still more specific embodiments the present methods include the step, wherein

    
    
        the continuous adding in step (b) above is achieved via an injector nozzle which is oriented at an angle of about 45° to the longitudinal axis of the high shear mixer and has a distance of about 2 to about 4 mm from the rotor of said high shear mixer which is operating with a tip speed of about 25 m/sec.
    
    


In other specific embodiments the present methods include the step, wherein

    
    
        the drying in step (g) above is achieved via fluidized bed drying.
    
    


In a further embodiment there are provided the solid dispersions obtained by the above-mentioned method.
The dried precipitate obtained by the above method can be further processed into any type of solid pharmaceutical preparations or dosage forms, which are known to the person of skill in the art. Particularly preferred are oral dosage forms such as tablets, capsules, pills, powders, suspensions, and the like.
Consequently, so obtained pharmaceutical preparations form further embodiments provided herein.
The term “organic solvent” mentioned under step (a) above means any organic solvent wherein both Compound I and HPMCAS are miscible. Preferred organic solvents are N-Methylpyrrolidone (NMP), Dimethylformamide (DMF), Dimethylsulfoxide (DMSO), Dimethylacetamide (DMA), and the like, with DMA being the most preferred. The combined amount of Compound I and HPMCAS together in the organic phase can be within the range of about 15 to 40 weight %, preferably about 25 to 40, most preferably about 35 weight %. The weight ratio of Compound I/HPMCAS in the organic solvent is about 30/70 weight %, respectively. Preferably, the temperature of the organic solvent is adjusted between 50 and 110° C., preferably 60 and 90° C., most preferred at about 70° C. prior to its addition to the mixing chamber as mentioned under step (b). The mixture of Compound I and HPMCAS in the organic solvent is also designated herein as the “organic phase” or “DMA phase”.
The term “aqueous phase” mentioned under step (b) preferably consists of acidic water (pH<7, preferably less than 3), most preferably of 0.01 N hydrochloric acid (HCl). The aqueous phase is kept at a temperature between about 0 and about 60° C., preferably between about 0 and 20° C., more preferred between about 5 and about 15° C., most preferably about 5° C. The aqueous phase circulates out of the bottom valve of its reservoir ((1) of FIG. 5) due to the stream created by the high shear mixer or with an auxiliary pump, preferably a rotary lobe pump, then passes through the high shear mixer, back into the reservoir. Preferably, the outlet of the loop is placed under the fluid level maintained in the reservoir, in order to prevent foaming.
The addition of the organic phase to the mixing chamber as mentioned in step (b) above is achieved via an injector nozzle which directly points into the aqueous phase. Any conventional nozzle known to the person of skill in the art can be used. Preferred injector nozzles show central or acentric geometry and have a diameter of about 1 to 10 mm. The acentric (not centered) geometry and a diameter of 5 mm are especially preferred. The injector nozzle may point to the rotor of the high shear mixing unit at an angle between 0 and 90°, preferably between 40 and 50°, most preferably at 45° (α, FIG. 6). During the process according to the present invention, the distance between the point of the injector nozzle and the tip of the rotor of the high shear mixing unit is about 1 to 10 mm, preferably about 2 to 4 mm and most preferably about 2.6 mm. The addition of the organic phase is preferably carried out at dosing rates of about 60/1 to about 300/1 (ratio of aqueous phase/organic phase during precipitation), preferably about 70/1 to about 120/1 and most preferably at about 100/1. Final ratio of aqueous phase/organic phase after precipitation is in the range of about 5/1-12/1 preferably 7/1-10/1 and most preferably at 8.5/1.
While the organic phase is added (injected) into the aqueous phase of the mixing chamber, the high shear mixing unit is operating. Any conventional high shear mixing unit (rotor/stator unit) known to the person of skill in the art can be applied. The preferred rotor geometry according to the present invention uses a rotor/stator unit with a radial single teeth row or double teeth row or combination thereof. The tip speed of the rotor is about 15 to about 25 m/sec., preferably 25 m/sec.
Subsequent to the complete addition of the organic phase into the aqueous phase, the obtained suspension, thus the precipitate consisting of amorphous Compound I and HPMCAS in the aqueous phase, is further circulated in the closed loop containing the high shear mixing unit. Outside of the high shear mixing unit the circulation must be carried out with the aid of an auxiliary pump, preferably a rotary lobe pump. The suspension is passed through the high shear mixing unit several times, up to the moment where a desired particle size and/or particle size distribution is obtained. Usually the suspension is passed through the high shear mixing unit about 1 to 60 times, most preferably 6 times. The particle size and/or particle size distribution can be determined by standard techniques, well known to the person of skill in the art, such as for example dynamic light scattering. The preferred particle size according to the present invention is with in the range of D50=80-230 μm preferably D50=80-160 μm.
Isolation of the solid dispersion (MBP) according to step (e) above can be carried out by using conventional filter techniques or centrifuges. Prior to isolation, the suspension is preferably adjusted to about 5 to 10° C. Subsequently, the isolated solid dispersion is washed with acidic water; preferably 0.01 N HCl followed by further washing with pure water in order to substantially remove the organic solvent (step (f)). The isolated (wet) solid dispersion (MBP) usually shows a water content between 60 and 70% (w/w), which is preferably dried before any further processing. The drying can be carried out using any standard techniques known to the person of skill in the art, for example using a cabinet dryer at temperatures between 30 and 50° C., preferably at about 40° C. and at reduced pressure, preferably below 20 mbar. Several drying procedures can be combined or used sequentially, whereby the use of fluidized bed drying is especially preferred as the final drying step according to the present invention.
A specific method of making the (HPMCAS-Compound I) MBP according to steps a) to g) above is described in Example 22, which forms a further preferred embodiment of the present invention. The stability of the solid dispersion (MBP) as obtained by the method of Example 22 was compared with the stability of an MBP obtained via conventional spray precipitation. “Conventional spray precipitation” means that the organic phase was sprayed onto the aqueous phase via a nozzle which is placed outside the aqueous phase, above its surface like is the case for many conventional spray-precipitation techniques. All further process parameters are the same for both methods. The stability, thus the inhibition of re-crystallization of Compound I, is determined by x-ray diffraction measurements, using a conventional wide angle X-ray scattering setup as it is well known to the skilled artisan. Sample preparation was identical for both MBP's. The samples were treated in a climate chamber (50° C. and 90% humidity (RH)) for several hours respective days (0 h, 14 h, 41 h, 4 d, 6 d, 13 d) prior to X-ray measurements. The results are shown in FIG. 7A for the MBP obtained according to Example 22, and FIG. 7B for the MBP obtained by the conventional method. The earliest X-ray curves of both MBP's show a broad halo in the wide angle region with the absence of sharp signals, thereby evidencing that both materials are in an amorphous state. Within several days, sharp signals occur in the X-ray curves obtained from the MBP manufactured by the conventional method (see FIG. 7B), but not in the X-ray curves obtained from the MBP prepared using the method disclosed herein (see FIG. 7A).
In summary, the results presented in FIGS. 7A and 7B demonstrate that the spray precipitated MBP is less stable against re-crystallization than the high shear precipitated MBP as evidenced by the early occurrence of sharp signals in the diffractograms (see FIG. 7B), which can be allocated to the crystalline form of Compound I. The bottom line in each figure represents the initial sample, the following lines bottom up after 14 h, 41 h, 96 h, 6 d respective 13 d storage in a climate controlled chamber (at 50° C. 90% RH).
The novel processes as provided herein can preferably be carried out using a setup as shown in the accompanying FIG. 5.
A setup substantially as illustrated in FIG. 5 can be used for the following preparation. Thus, FIG. 5 contemplates two reservoirs (vessels) with temperature control means, one for providing the aqueous phase at a controlled temperature (1), the other for providing the organic phase at a controlled temperature (2). Both vessels are further equipped with automatic stirrers (3). The aqueous phase is circulated in a closed loop (4) using a pump (5), while passing through a high shear mixing unit (6). The organic phase is added into the aqueous phase within the high shear mixing unit with the aid of a dosing pump (7) and via an injector nozzle which is shown in more detail in FIG. 6.
As shown in FIG. 6, the nozzle (8) is placed within the aqueous phase inside the high shear mixing unit. The nozzle can be oriented within different angles (α) with respect to the rotor (9) of the high shear mixing unit, and within defined distances (d) of the rotor tip.
The solid dispersion, in particular the MBP obtainable according to the methods provided can be used in a wide variety of forms for administration of drugs such as Compound I, including drugs that are poorly water soluble, and in particular for oral dosage forms. Exemplary dosage forms include powders or granules that can be taken orally either dry or reconstituted by addition of water to form a paste, slurry, suspension or solution; tablets, capsules, or pills. Various additives can be mixed, ground or granulated with the solid dispersion as described herein to form a material suitable for the above dosage forms. Potentially beneficial additives may fall generally into the following classes: other matrix materials or diluents, surface active agents, drug complexing agents or solubilizers, fillers, disintegrants, binders, lubricants, and pH modifiers (e.g., acids, bases, or buffers). Examples of other matrix materials, fillers, or diluents include lactose, mannitol, xylitol, microcrystalline cellulose, calcium diphosphate, and starch. Examples of surface active agents include sodium lauryl sulfate and polysorbate 80. Examples of drug complexing agents or solubilizers include the polyethylene glycols, caffeine, xanthene, gentisic acid and cylodextrins. Examples of disintegrants include sodium starch gycolate, sodium alginate, carboxymethyl cellulose sodium, methyl cellulose, and croscarmellose sodium. Examples of binders include methyl cellulose, microcrystalline cellulose, starch, and gums such as guar gum, and tragacanth. Examples of lubricants include magnesium stearate and calcium stearate. Examples of pH modifiers include acids such as citric acid, acetic acid, ascorbic acid, lactic acid, aspartic acid, succinic acid, phosphoric acid, and the like; bases such as sodium acetate, potassium acetate, calcium oxide, magnesium oxide, trisodium phosphate, sodium hydroxide, calcium hydroxide, aluminum hydroxide, and the like, and buffers generally comprising mixtures of acids and the salts of said acids. At least one function of inclusion of such pH modifiers is to control the dissolution rate of the drug, matrix polymer, or both, thereby controlling the local drug concentration during dissolution.
Additives may be incorporated into the solid amorphous dispersion during or after its formation. In addition to the above additives or excipients, use of any conventional materials and procedures for formulation and preparation of oral dosage forms using the compositions disclosed herein known by those skilled in the art are potentially useful.
Consequently, a further embodiment includes a pharmaceutical preparation containing the solid dispersion as obtained by a method as described herein, in particular as obtained according to steps a) to g) as mentioned above, and more particularly as obtained according to the process described in Example 22.
In still another embodiment, there is provided a solid dispersion as obtained according to the present process for use as a medicament, in particular a solid dispersion comprising HPMCAS and Compound I, more particularly the solid dispersion as obtained according the steps a) to g) above or according to Example 22.
In yet another embodiment there is provided the use of the solid dispersion obtainable by the present steps a) to g) or by the method of Example 22 in the manufacture of medicaments for the treatment of cancer, in particular solid tumors, and more particularly malignant (metastatic) melanomas.
In still another embodiment, there is provided the solid dispersion as obtained according to steps a) to g) above or the method of Example 22 for use as a medicament for the treatment of cancer, in particular solid tumors, and more particularly malignant (metastatic) melanoma.
c) pH-Controlled Precipitation
The process involves the microprecipitation of Compound I in an ionic polymer (for example, HPMC-AS). In this process, Compound I and the polymer are dissolved at a high pH and precipitated by lowering the pH of the solution or vice versa.
In a preferred embodiment, the polymer is HPMC-AS which is insoluble at low pH. Compound I and HPMC-AS are dissolved in an organic solvent such as dimethylformamide, dimethylacetamide (DMA), dimethyl sulfoxide (DMSO), N-methylpyrrolidone (NMP), and the like. The pH of the solution is then lowered, for example by adding an acid. Addition of the acid includes mixing of the Compound I and polymer solution and the acid, for example by adding acid to the Compound I and polymer solution, adding the Compound I and polymer solution to the acid, or mixing the two simultaneously. At the lowered pH, both Compound I and HPMC-AS simultaneously precipitate out, resulting in a solid molecular complex containing Compound I embedded in a matrix formed by HPMC-AS. The resulting solid molecular complex may then be washed with water to remove the organic solvent.
d) Hot Melt Extrusion Process
Microprecipitation of the Compound I in a polymer (such as HPMC-AS) can be achieved in certain embodiments by a hot melt extrusion process. Compound I and the polymer are mixed and then fed continuously to a temperature-controlled extruder causing the Compound Ito be molecularly dispersed in the molten polymer. The resulting extrudate is cooled to room temperature and milled into a fine powder.
e) Supercritical Fluid Process
In this process Compound I and a polymer (such as HPMC-AS) are dissolved in a supercritical fluid such as liquid nitrogen or liquid carbon dioxide. The supercritical fluid is then removed by evaporation leaving the Compound I microprecipitated in the matrix formed by the polymer. In a different method, the Compound I and a polymer (such as HPMC-AS) are dissolved in a suitable solvent. A microprecipitated powder can then be formed by spraying the solution in a supercritical fluid which acts as an antisolvent.
The resulting solid molecular complex prepared by any method may be further processed to provide suitable bioavailability. The solid molecular complex may be processed by roller compaction, for example the complex and other powders may be blended and roller compacted to form a ribbon or sheet that is then milled, mixed with other excipients and encapsulated into 2-pc hard gelatin capsule shells at the desired strength.
Determination of Whether Compound I is in Amorphous Form
Whether Compound I has been successfully immobilized in amorphous form can be determined by various means, including powder X-ray diffraction. In addition, the glass transition temperature of the complex can be measured using modulated DSC and this can also provide information whether the dispersion is a multiphase or uniphase. A uniphase is indicative of such immobilization.
Crystalline Polymorphs
(A) Crystalline Polymorph Form 1
Crystalline polymorphs of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide (Compound I) are provided. In one embodiment, crystalline polymorph Form 1 is provided, wherein the polymorph exhibits a powder x-ray diffraction pattern having characteristic peak locations of approximately 4.7, 9.4, 11.0, 12.5, and 15.4 degrees 2θ. In one embodiment, polymorph Form 1 exhibits a powder x-ray diffraction pattern having characteristic peak locations of approximately 4.7, 9.4, 10.0, 11.0, 12.5, 14.2, 15.4, 18.6, and 22.2 degrees 2θ. In one embodiment, polymorph Form 1 exhibits a powder x-ray diffraction pattern having characteristic peak locations of approximately 4.7, 9.4, 10.0, 11.0, 12.5, 14.2, 15.4, 16.1, 18.6, 19.0, 22.2 and 26.8 degrees 2θ. In one embodiment, crystalline polymorph Form 1 exhibits a powder x-ray diffraction pattern substantially the same as the powder x-ray diffraction pattern of FIG. 1. In one embodiment, a purified crystalline polymorph Form 1 is provided. In one embodiment, a purified crystalline polymorph Form 1 is used in the preparation of a mesylate or tosylate salt form of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide. In one embodiment, a pharmaceutical composition comprising crystalline polymorph Form 1 and at least one excipient or carrier is provided.
Methods of making crystalline polymorph Form 1 of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide are provided. The method may include recrystallization of any form of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide from a mixture of a lower ketone and a lower alcohol, e.g., acetone:absolute ethanol. The propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide may be recrystallized from acetone:absolute ethanol in a ratio of from 1:1 to 5:1, preferably 2:1 by volume.
(B) Crystalline Polymorph Form 2
Crystalline polymorph Form 2 of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide is provided, wherein the polymorph exhibits a powder x-ray diffraction pattern having characteristic peak locations of approximately 8.8, 9.2, 13.5, 19.1 and 24.4 degrees 2θ. In one embodiment, polymorph Form 2 exhibits a powder x-ray diffraction pattern having characteristic peak locations of approximately 6.7, 8.8, 9.2, 13.5, 15.0, 17.7, 19.1, 19.7, 21.4 and 24.4 degrees 2θ. In one embodiment, polymorph Form 2 exhibits a powder x-ray diffraction pattern having characteristic peak locations of approximately 6.7, 8.8, 9.2, 13.5, 14.1, 14.5, 15.0, 16.2, 17.0, 17.7, 19.1, 19.7, 21.4, 22.2, 24.1, 24.4, and 28.1 degrees 2θ. In one embodiment, crystalline polymorph Form 2 exhibits a powder x-ray diffraction pattern substantially the same as the powder x-ray diffraction pattern of FIG. 2. In one embodiment, a purified crystalline polymorph Form 2 is provided. In one embodiment, a purified crystalline polymorph Form 2 is used in the preparation of a mesylate or tosylate salt form of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide. In one embodiment, a pharmaceutical composition comprising crystalline polymorph Form 2 and at least one excipient or carrier is provided.
Methods of making crystalline polymorph Form 2 of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide are provided, wherein the method comprises direct crystallization from dimethylacetamide/methanol and recrystallization of any form of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide from a suitable ether (including cyclic ethers), ester or ketone solvent such as methyl-t-butyl ether:tetrahydrofuran, ethyl acetate, or acetone. In one embodiment, Form 2 of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide is prepared by heating/melting any form of the compound and re-solidifying.
Mesylate Salt of Compound I
A mesylate salt form of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide is provided. In one embodiment, a mesylate salt form of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide is provided. In one embodiment, the mesylate salt form is substantially crystalline. In one embodiment, the mesylate salt form is partially amorphous. In one embodiment, the mesylate salt form is substantially amorphous. In one embodiment, the mesylate salt is used in a microprecipitated bulk process to formulate the salt in an amorphous form. In one embodiment, the mesylate salt is generated in situ in a microprecipitated bulk process to formulate the salt in an amorphous form. In one embodiment, a composition is provided comprising the mesylate salt.
Tosylate Salt of Compound I
A tosylate salt of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide is provided. In one embodiment, the tosylate salt form is substantially crystalline. In one embodiment, the tosylate salt form is partially amorphous. In one embodiment, the tosylate salt form is substantially amorphous. In one embodiment, the tosylate salt is used in a microprecipitated bulk process to formulate the salt in an amorphous form. In one embodiment, the tosylate salt is generated in situ in a microprecipitated bulk process to formulate the salt in an amorphous form. In one embodiment, a composition is provided comprising the tosylate salt.
Kinase Targets and Indications
Protein kinases play key roles in propagating biochemical signals in diverse biological pathways. More than 500 kinases have been described, and specific kinases have been implicated in a wide range of diseases or conditions (i.e., indications), including for example without limitation, cancer, cardiovascular disease, inflammatory disease, neurological disease, and other diseases. As such, kinases represent important control points for small molecule therapeutic intervention. Description of specific target protein kinases contemplated by the present invention follow:
A-Raf: Target kinase A-Raf (i.e., v-raf murine sarcoma 3611 viral oncogene homolog 1) is a 67.6 kDa serine/threonine kinase encoded by chromosome Xp11.4-p11.2 (symbol: ARAF). The mature protein comprises RBD (i.e., Ras binding domain) and phorbol-ester/DAG-type zinc finger domain and is involved in the transduction of mitogenic signals from the cell membrane to the nucleus. A-Raf inhibitors may be useful in treating neurologic diseases such as multi-infarct dementia, head injury, spinal cord injury, Alzheimer's disease (AD), Parkinson's disease; neoplastic diseases including, but not limited to, melanoma, glioma, sarcoma, carcinoma (e.g. colorectal, lung, breast, pancreatic, thyroid, renal, ovarian), lymphoma (e.g. histiocytic lymphoma), neurofibromatosis, myelodysplastic syndrome, leukemia, tumor angiogenesis; pain of neuropathic or inflammatory origin, including acute pain, chronic pain, cancer-related pain and migraine; and diseases associated with muscle regeneration or degeneration, including, but not limited to, vascular restenosis, sarcopenia, muscular dystrophies (including, but not limited to, Duchenne, Becker, Emery-Dreifuss, Limb-Girdle, Facioscapulohumeral, Myotonic, Oculopharyngeal, Distal and Congenital Muscular Dystrophies), motor neuron diseases (including, but not limited to, amyotrophic lateral sclerosis, infantile progressive spinal muscular atrophy, intermediate spinal muscular atrophy, juvenile spinal muscular atrophy, spinal bulbar muscular atrophy, and adult spinal muscular atrophy), inflammatory myopathies (including, but not limited to, dermatomyositis, polymyositis, and inclusion body myositis), diseases of the neuromuscular junction (including, but not limited to, myasthenia gravis, Lambert-Eaton syndrome, and congenital myasthenic syndrome), myopathies due to endocrine abnormalities (including, but not limited to, hyperthyroid myopathy and hypothyroid myopathy) diseases of peripheral nerve (including, but not limited to, Charcot-Marie-Tooth disease, Dejerine-Sottas disease, and Friedreich's ataxia), other myopathies (including, but not limited to, myotonia congenita, paramyotonia congenita, central core disease, nemaline myopathy, myotubular myopathy, and periodic paralysis), and metabolic diseases of muscle (including, but not limited to, phosphorylase deficiency, acid maltase deficiency, phosphofructokinase deficiency, debrancher enzyme deficiency, mitochondrial myopathy, carnitine deficiency, carnitine palmatyl transferase deficiency, phosphoglycerate kinase deficiency, phosphoglycerate mutase deficiency, lactate dehydrogenase deficiency, and myoadenylate deaminase deficiency).
B-Raf: Target kinase B-Raf (i.e., v-raf murine sarcoma viral oncogene homolog B1) is a 84.4 kDa serine/threonine kinase encoded by chromosome 7q34 (symbol: BRAF). The mature protein comprises RBD (i.e., Ras binding domain), C1 (i.e., protein kinase C conserved region 1) and STK (i.e., serine/threonine kinase) domains.
Target kinase B-Raf is involved in the transduction of mitogenic signals from the cell membrane to the nucleus and may play a role in the postsynaptic responses of hippocampal neurons. As such, genes of the RAF family encode kinases that are regulated by Ras and mediate cellular responses to growth signals. Indeed, B-Raf kinase is a key component of the RAS->Raf->MEK->ERK/MAP kinase signaling pathway, which plays a fundamental role in the regulation of cell growth, division and proliferation, and, when constitutively activated, causes tumorigenesis. Among several isoforms of Raf kinase, the B-type, or B-Raf, is the strongest activator of the downstream MAP kinase signaling.
The BRAF gene is frequently mutated in a variety of human tumors, especially in malignant melanoma and colon carcinoma. The most common reported mutation was a missense thymine (T) to adenine (A) transversion at nucleotide 1796 (T1796A; amino acid change in the B-Raf protein is Val<600> to Glu<600>) observed in 80% of malignant melanoma tumors. Functional analysis reveals that this transversion is the only detected mutation that causes constitutive activation of B-Raf kinase activity, independent of RAS activation, by converting B-Raf into a dominant transforming protein. Based on precedents, human tumors develop resistance to kinase inhibitors by mutating a specific amino acid in the catalytic domain as the “gatekeeper”. (Balak, et. al., Clin Cancer Res. 2006, 12:6494-501). Mutation of Thr-529 in BRAF to De is thus anticipated as a mechanism of resistance to BRAF inhibitors, and this can be envisioned as a transition in codon 529 from ACC to ATC.
Niihori et al., report that in 43 individuals with cardio-facio-cutaneous (CFC) syndrome, they identified two heterozygous KRAS mutations in three individuals and eight BRAF mutations in 16 individuals, suggesting that dysregulation of the RAS-RAF-ERK pathway is a common molecular basis for the three related disorders (Niihori et al., Nat. Genet. 2006, 38(3):294-6).
c-Raf-1: Target kinase c-Raf-1 (i.e., v-raf murine sarcoma viral oncogene homolog 1) is a 73.0 kDa STK encoded by chromosome 3p25 (symbol: RAF1). c-Raf-1 can be targeted to the mitochondria by BCL2 (i.e., oncogene B-cell leukemia 2) which is a regulator of apoptotic cell death. Active c-Raf-1 improves BCL2-mediated resistance to apoptosis, and c-Raf-1 phosphorylates BAD (i.e., BCL2-binding protein). c-Raf-1 is implicated in carcinomas, including colorectal, ovarian, lung and renal cell carcinoma. C-Raf-1 is also implicated as an important mediator of tumor angiogenesis (Hood, J. D. et al., 2002, Science 296, 2404). C-Raf-1 inhibitors may also be useful for the treatment of acute myeloid leukemia and myelodysplastic syndromes (Crump, Curr Pharm Des 2002, 8(25):2243-8). Raf-1 activators may be useful as treatment for neuroendocrine tumors, such as medullary thyroid cancer, carcinoid, small cell lung cancer and pheochromocytoma (Kunnimalaiyaan et al., Anticancer Drugs 2006, 17(2):139-42).
A-Raf, B-Raf and/or C-Raf inhibitors may be useful in treating A-Raf-mediated, B-Raf-mediated or c-Raf-1-mediated disease or condition selected from the group consisting of neurologic diseases, including, but not limited to, multi-infarct dementia, head injury, spinal cord injury, Alzheimer's disease (AD), Parkinson's disease, seizures and epilepsy; neoplastic diseases including, but not limited to, melanoma, glioma, sarcoma, carcinoma (e.g. gastrointestinal, liver, bile duct (cholangiocarcinoma), colorectal, lung, breast, pancreatic, thyroid, renal, ovarian, prostate), lymphoma (e.g. histiocytic lymphoma) neurofibromatosis, acute myeloid leukemia, myelodysplastic syndrome, leukemia, tumor angiogenesis, neuroendocrine tumors such as medullary thyroid cancer, carcinoid, small cell lung cancer, Kaposi's sarcoma, and pheochromocytoma; pain of neuropathic or inflammatory origin, including, but not limited to, acute pain, chronic pain, cancer-related pain, and migraine; cardiovascular diseases including, but not limited to, heart failure, ischemic stroke, cardiac hypertrophy, thrombosis (e.g. thrombotic microangiopathy syndromes), atherosclerosis, and reperfusion injury; inflammation and/or proliferation including, but not limited to, psoriasis, eczema, arthritis and autoimmune diseases and conditions, osteoarthritis, endometriosis, scarring, vascular restenosis, fibrotic disorders, rheumatoid arthritis, inflammatory bowel disease (IBD); immunodeficiency diseases, including, but not limited to, organ transplant rejection, graft versus host disease, and Kaposi's sarcoma associated with HIV; renal cystic, or prostatic diseases, including, but not limited to, diabetic nephropathy, polycystic kidney disease, nephrosclerosis, glomerulonephritis, prostate hyperplasia, polycystic liver disease, tuberous sclerosis, Von Hippel Lindau disease, medullary cystic kidney disease, nephronophthisis, and cystic fibrosis; metabolic disorders, including, but not limited to, obesity; infection, including, but not limited to Helicobacter pylori, Hepatitis and Influenza viruses, fever, HIV and sepsis; pulmonary diseases including, but not limited to, chronic obstructive pulmonary disease (COPD) and acute respiratory distress syndrome (ARDS); genetic developmental diseases, including, but not limited to Noonan's syndrome, Costello syndrome, (faciocutaneoskeletal syndrome), LEOPARD syndrome, cardio-facio-cutaneous syndrome (CFC), and neural crest syndrome abnormalities causing cardiovascular, skeletal, intestinal, skin, hair and endocrine diseases; and diseases associated with muscle regeneration or degeneration, including, but not limited to, sarcopenia, muscular dystrophies (including, but not limited to, Duchenne, Becker, Emery-Dreifuss, Limb-Girdle, Facioscapulohumeral, Myotonic, Oculopharyngeal, Distal and Congenital Muscular Dystrophies), motor neuron diseases (including, but not limited to, amyotrophic lateral sclerosis, infantile progressive spinal muscular atrophy, intermediate spinal muscular atrophy, juvenile spinal muscular atrophy, spinal bulbar muscular atrophy, and adult spinal muscular atrophy), inflammatory myopathies (including, but not limited to, dermatomyositis, polymyositis, and inclusion body myositis), diseases of the neuromuscular junction (including, but not limited to, myasthenia gravis, Lambert-Eaton syndrome, and congenital myasthenic syndrome), myopathies due to endocrine abnormalities (including, but not limited to, hyperthyroid myopathy and hypothyroid myopathy) diseases of peripheral nerve (including, but not limited to, Charcot-Marie-Tooth disease, Dejerine-Sottas disease, and Friedreich's ataxia), other myopathies (including, but not limited to, myotonia congenita, paramyotonia congenita, central core disease, nemaline myopathy, myotubular myopathy, and periodic paralysis), and metabolic diseases of muscle (including, but not limited to, phosphorylase deficiency, acid maltase deficiency, phosphofructokinase deficiency, debrancher enzyme deficiency, mitochondrial myopathy, carnitine deficiency, carnitine palmatyl transferase deficiency, phosphoglycerate kinase deficiency, phosphoglycerate mutase deficiency, lactate dehydrogenase deficiency, and myoadenylate deaminase deficiency).
Alternative Compound Forms or Derivatives
Propane-1-sulfonic acid {3-[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl-2,4-difluoro-phenyl]-amide} contemplated herein is described with reference to the specific compound. In addition, Compound I may exist in a number of different forms or derivatives, all within the scope of the present inventions. Alternative forms or derivatives, include, for example, (a) prodrugs, and active metabolites (b) tautomers (c) pharmaceutically acceptable salts and (d) solid forms, including different crystal forms, polymorphic or amorphous solids, including hydrates and solvates thereof, and other forms.
Prodrugs and Metabolites
Prodrugs are compounds or pharmaceutically acceptable salts thereof which, when metabolized under physiological conditions or when converted by solvolysis, yield the desired active compound. Prodrugs include, without limitation, esters, amides, carbamates, carbonates, ureides, solvates, or hydrates of the active compound. Typically, the prodrug is inactive, or less active than the active compound, but may provide one or more advantageous handling, administration, and/or metabolic properties. Prodrugs may include variants wherein an —NH group of the compound has undergone acylation, such as the 1-position of the pyrrolo[2,3-b]pyridine ring or the nitrogen of the sulfonamide group of Compound I or a pharmaceutically acceptable salt thereof, where cleavage of the acyl group provides the free —NH group of the active drug. Some prodrugs are activated enzymatically to yield the active compound, or a compound may undergo further chemical reaction to yield the active compound. Prodrugs may proceed from prodrug form to active form in a single step or may have one or more intermediate forms which may themselves have activity or may be inactive.
As described in The Practice of Medicinal Chemistry, Ch. 31-32 (Ed. Wermuth, Academic Press, San Diego, Calif., 2001), prodrugs can be conceptually divided into two non-exclusive categories, bioprecursor prodrugs and carrier prodrugs. Generally, bioprecursor prodrugs are compounds that are inactive or have low activity compared to the corresponding active drug compound, that contain one or more protective groups and are converted to an active form by metabolism or solvolysis. Both the active drug form and any released metabolic products should have acceptably low toxicity. Typically, the formation of active drug compound involves a metabolic process or reaction that is one of the following types:
Oxidative reactions: Oxidative reactions are exemplified without limitation by reactions such as oxidation of alcohol, carbonyl, and acid functionalities, hydroxylation of aliphatic carbons, hydroxylation of alicyclic carbon atoms, oxidation of aromatic carbon atoms, oxidation of carbon-carbon double bonds, oxidation of nitrogen-containing functional groups, oxidation of silicon, phosphorus, arsenic, and sulfur, oxidative N-dealkylation, oxidative O— and S -dealkylation, oxidative deamination, as well as other oxidative reactions.
Reductive reactions: Reductive reactions are exemplified without limitation by reactions such as reduction of carbonyl functionalities, reduction of alcohol functionalities and carbon-carbon double bonds, reduction of nitrogen-containing functional groups, and other reduction reactions.
Reactions without change in the oxidation state: Reactions without change in the state of oxidation are exemplified without limitation to reactions such as hydrolysis of esters and ethers, hydrolytic cleavage of carbon-nitrogen single bonds, hydrolytic cleavage of non-aromatic heterocycles, hydration and dehydration at multiple bonds, new atomic linkages resulting from dehydration reactions, hydrolytic dehalogenation, removal of hydrogen halide molecule, and other such reactions.
Carrier prodrugs are drug compounds that contain a transport moiety, e.g., that improves uptake and/or localized delivery to a site(s) of action. Desirably for such a carrier prodrug, the linkage between the drug moiety and the transport moiety is a covalent bond, the prodrug is inactive or less active than the drug compound, the prodrug and any release transport moiety are acceptably non-toxic. For prodrugs where the transport moiety is intended to enhance uptake, typically the release of the transport moiety should be rapid. In other cases, it is desirable to utilize a moiety that provides slow release, e.g., certain polymers or other moieties, such as cyclodextrins. (See, e.g., Cheng et al., U.S. Patent Publ. No. 20040077595, application Ser. No. 10/656,838, incorporated herein by reference.) Such carrier prodrugs are often advantageous for orally administered drugs. In some instances, the transport moiety provides targeted delivery of the drug, for example the drug may be conjugated to an antibody or antibody fragment. Carrier prodrugs can, for example, be used to improve one or more of the following properties: increased lipophilicity, increased duration of pharmacological effects, increased site-specificity, decreased toxicity and adverse reactions, and/or improvement in drug formulation (e.g., stability, water solubility, suppression of an undesirable organoleptic or physiochemical property). For example, lipophilicity can be increased by esterification of hydroxyl groups with lipophilic carboxylic acids, or of carboxylic acid groups with alcohols, e.g., aliphatic alcohols. Wermuth, supra.
Metabolites, e.g., active metabolites, overlap with prodrugs as described above, e.g., bioprecursor prodrugs. Thus, such metabolites are pharmacologically active compounds or compounds that further metabolize to pharmacologically active compounds that are derivatives resulting from metabolic processes in the body of a subject. Of these, active metabolites are such pharmacologically active derivative compounds. For prodrugs, the prodrug compound is generally inactive or of lower activity than the metabolic product. For active metabolites, the parent compound may be either an active compound or may be an inactive prodrug. For example, in some compounds, one or more alkoxy groups can be metabolized to hydroxyl groups while retaining pharmacologic activity and/or carboxyl groups can be esterified, e.g., glucuronidation. In some cases, there can be more than one metabolite, where an intermediate metabolite(s) is further metabolized to provide an active metabolite. For example, in some cases a derivative compound resulting from metabolic glucuronidation may be inactive or of low activity, and can be further metabolized to provide an active metabolite.
Metabolites of a compound may be identified using routine techniques known in the art, and their activities determined using tests such as those described herein. See, e.g., Bertolini et al., 1997, J. Med. Chem., 40:2011-2016; Shan et al., 1997, J Pharm Sci 86(7):756-757; Bagshawe, 1995, Drug Dev. Res., 34:220-230; Wermuth, supra.
Tautomers
It is understood that some compounds may exhibit tautomerism. In such cases, the formulae provided herein expressly depict only one of the possible tautomeric forms. It is therefore to be understood that Compound I provided herein is intended to represent any tautomeric form of the depicted compound and is not to be limited merely to the specific tautomeric form depicted by the drawing of the compound.
Pharmaceutically Acceptable Salts
Unless specified to the contrary, specification of Compound I herein includes pharmaceutically acceptable salts of such compound. Thus, Compound I can be in the form of pharmaceutically acceptable salts, or can be formulated as pharmaceutically acceptable salts. Contemplated pharmaceutically acceptable salt forms include, without limitation, mono, bis, tris, tetrakis, and so on. Pharmaceutically acceptable salts are non-toxic in the amounts and concentrations at which they are administered. The preparation of such salts can facilitate the pharmacological use by altering the physical characteristics of a compound without preventing it from exerting its physiological effect. Useful alterations in physical properties include lowering the melting point to facilitate transmucosal administration and increasing the solubility to facilitate administering higher concentrations of the drug. Compound I possesses a sufficiently acidic and a sufficiently basic functional group, and accordingly can react with any of a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt.
Pharmaceutically acceptable salts include acid addition salts such as those containing chloride, bromide, iodide, hydrochloride, acetate, dichloroacetate, phenylacetate, acrylate, ascorbate, aspartate, benzoate, 2-phenoxybenzoate, 2-acetoxybenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, methylbenzoate, bicarbonate, butyne-1,4 dioate, hexyne-1,6-dioate, caproate, caprylate, chlorobenzoate, cinnamate, citrate, decanoate, formate, fumarate, glycolate, gluconate, glucarate, glucuronate, glucose-6-phosphate, glutamate, heptanoate, hexanoate, isethionate, isobutyrate, gamma-hydroxybutyrate, phenylbutyrate, lactate, malate, maleate, hydroxymaleate, methylmaleate, malonate, mandelate, nicotinate, nitrate, isonicotinate, octanoate, oleate, oxalate, pamoate, phosphate, monohydrogenphosphate, dihydrogenphosphate, orthophosphate, metaphosphate, pyrophosphate, 2-phosphoglycerate, 3-phosphoglycerate, phthalate, propionate, phenylpropionate, propiolate, pyruvate, quinate, salicylate, 4-aminosalicylate, sebacate, stearate, suberate, succinate, sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, sulfamate, sulfonate, benzenesulfonate (i.e. besylate), ethanesulfonate (i.e. esylate), ethane-1,2-disulfonate, 2-hydroxyethanesulfonate (i.e. isethionate), methanesulfonate (i.e. mesylate), naphthalene-1-sulfonate, naphthalene-2-sulfonate (i.e. napsylate), propanesulfonate, p-toluenesulfonate (i.e. tosylate), xylenesulfonates, cyclohexylsulfamate, tartrate, and trifluoroacetate. These pharmaceutically acceptable acid addition salts can be prepared using the appropriate corresponding acid.
When acidic functional groups, such as carboxylic acid or phenol are present, pharmaceutically acceptable salts also include basic addition salts such as those containing benzathine, chloroprocaine, choline, ethanolamine, diethanolamine, triethanolamine, t-butylamine, dicyclohexylamine, ethylenediamine, N,N′-dibenzylethylenediamine, meglumine, hydroxyethylpyrrolidine, piperidine, morpholine, piperazine, procaine, aluminum, calcium, copper, iron, lithium, magnesium, manganese, potassium, sodium, zinc, ammonium, and mono-, di-, or tri-alkylamines (e.g. diethylamine), or salts derived from amino acids such as L-histidine, L-glycine, L-lysine, and L-arginine. For example, see Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Co., Easton, Pa., Vol. 2, p. 1457, 1995. These pharmaceutically acceptable base addition salts can be prepared using the appropriate corresponding base.
Pharmaceutically acceptable salts can be prepared by standard techniques. For example, the free-base form of a compound can be dissolved in a suitable solvent, such as an aqueous or aqueous-alcohol solution containing the appropriate acid and then isolated by evaporating the solution. In another example, a salt can be prepared by reacting the free base and acid in an organic solvent. If the particular compound is an acid, the desired pharmaceutically acceptable salt may be prepared by any suitable method, for example, treatment of the free acid with an appropriate inorganic or organic base.
Other Compound Forms
In the case of agents that are solids, it is understood by those skilled in the art that the compounds and salts may exist in different crystal or polymorphic forms, or may be formulated as co-crystals, or may be in an amorphous form, or may be any combination thereof (e.g. partially crystalline, partially amorphous, or mixtures of polymorphs) all of which are intended to be within the scope of the present invention and specified formulae. Whereas salts are formed by acid/base addition, i.e. a free base or free acid of the compound of interest forms an acid/base reaction with a corresponding addition base or addition acid, respectively, resulting in an ionic charge interaction, co-crystals are a new chemical species that is formed between neutral compounds, resulting in the compound and an additional molecular species in the same crystal structure.
In some instances, Compound I is complexed with an acid or a base, including base addition salts such as ammonium, diethylamine, ethanolamine, ethylenediamine, diethanolamine, t-butylamine, piperazine, meglumine; acid addition salts, such as acetate, acetylsalicylate, besylate, camsylate, citrate, formate, fumarate, glutarate, hydrochlorate, maleate, mesylate, nitrate, oxalate, phosphate, succinate, sulfate, tartrate, thiocyanate and tosylate; and amino acids such as alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine or valine. In combining Compound I with the acid or base, an amorphous complex is preferably formed rather than a crystalline material such as a typical salt or co-crystal. In some instances, the amorphous form of the complex is facilitated by additional processing, such as by spray-drying, mechanochemical methods such as roller compaction, or microwave irradiation of the parent compound mixed with the acid or base. Such amorphous complexes provide several advantages. For example, lowering of the melting temperature relative to the free base facilitates additional processing, such as hot melt extrusion, to further improve the biopharmaceutical properties of the compound. Also, the amorphous complex is readily friable, which provides improved compression for loading of the solid into capsule or tablet form.
Additionally, Compound I or salts thereof described herein are intended to cover hydrated or solvated as well as unhydrated or unsolvated forms of the identified material. For example, Compound I or salts thereof includes both hydrated and non-hydrated forms. Other examples of solvates include the structures in combination with a suitable solvent, such as isopropanol, ethanol, methanol, DMSO, ethyl acetate, acetic acid, or ethanolamine.
Formulations and Administration
Compound I or any form thereof as described herein (including solid molecular complexes) will typically be used in therapy for human subjects. However, Compound I and compositions thereof may also be used to treat similar or identical indications in other animal subjects, and can be administered by different routes, including injection (i.e. parenteral, including intravenous, intraperitoneal, subcutaneous, and intramuscular), oral, transdermal, transmucosal, rectal, or inhalant. Such dosage forms should allow the compound to reach target cells. Other factors are well known in the art, and include considerations such as toxicity and dosage forms that retard the compound or composition from exerting its effects. Techniques and formulations generally may be found in Remington: The Science and Practice of Pharmacy, 21st edition, Lippincott, Williams and Wilkins, Philadelphia, Pa., 2005 (hereby incorporated by reference herein).
In some embodiments, compositions (including solid complexes as disclosed herein) include pharmaceutically acceptable carriers or excipients, such as fillers, binders, disintegrants, glidants, lubricants, complexing agents, solubilizers, and surfactants, which may be chosen to facilitate administration of the compound by a particular route. Examples of carriers include calcium carbonate, calcium phosphate, various sugars such as lactose, glucose, or sucrose, types of starch, cellulose derivatives, gelatin, lipids, liposomes, nanoparticles, and the like. Carriers also include physiologically compatible liquids as solvents or for suspensions, including, for example, sterile solutions of water for injection (WFI), saline solution, dextrose solution, Hank's solution, Ringer's solution, vegetable oils, mineral oils, animal oils, polyethylene glycols, liquid paraffin, and the like. Excipients may also include, for example, colloidal silicon dioxide, silica gel, talc, magnesium silicate, calcium silicate, sodium aluminosilicate, magnesium trisilicate, powdered cellulose, macrocrystalline cellulose, carboxymethyl cellulose, cross-linked sodium carboxymethylcellulose, sodium benzoate, calcium carbonate, magnesium carbonate, stearic acid, aluminum stearate, calcium stearate, magnesium stearate, zinc stearate, sodium stearyl fumarate, syloid, stearowet C, magnesium oxide, starch, sodium starch glycolate, glyceryl monostearate, glyceryl dibehenate, glyceryl palmitostearate, hydrogenated vegetable oil, hydrogenated cotton seed oil, castor seed oil mineral oil, polyethylene glycol (e.g. PEG 4000-8000), polyoxyethylene glycol, poloxamers, povidone, crospovidone, croscarmellose sodium, alginic acid, casein, methacrylic acid divinylbenzene copolymer, sodium docusate, cyclodextrins (e.g. 2-hydroxypropyl-.delta.-cyclodextrin), polysorbates (e.g. polysorbate 80), cetrimide, TPGS (d-alpha-tocopheryl polyethylene glycol 1000 succinate), magnesium lauryl sulfate, sodium lauryl sulfate, polyethylene glycol ethers, di-fatty acid ester of polyethylene glycols, or a polyoxyalkylene sorbitan fatty acid ester (e.g., polyoxyethylene sorbitan ester Tween®), polyoxyethylene sorbitan fatty acid esters, sorbitan fatty acid ester, e.g. a sorbitan fatty acid ester from a fatty acid such as oleic, stearic or palmitic acid, mannitol, xylitol, sorbitol, maltose, lactose, lactose monohydrate or lactose spray dried, sucrose, fructose, calcium phosphate, dibasic calcium phosphate, tribasic calcium phosphate, calcium sulfate, dextrates, dextran, dextrin, dextrose, cellulose acetate, maltodextrin, simethicone, polydextrosem, chitosan, gelatin, HPMC (hydroxypropylmethyl celluloses), HPC (hydroxypropyl cellulose), hydroxyethyl cellulose, hypromellose, and the like.
In an embodiment of the present invention, a formulation is provided which comprises the aforementioned solid complex suspended in an aqueous vehicle. The formulation may further comprise colloidal silicon dioxide which has been found to stabilize the suspension. The silicon dioxide is preferably present in an amount of at least 0.5% by weight of the formulation. The aqueous vehicle preferably is about 2% by weight hydroxypropyl cellulose.
In some embodiments, oral administration may be used. Pharmaceutical preparations for oral use can be formulated into conventional oral dosage forms such as capsules, tablets, and liquid preparations such as syrups, elixirs, and concentrated drops. Compound I may be combined with solid excipients, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain, for example, tablets, coated tablets, hard capsules, soft capsules, solutions (e.g. aqueous, alcoholic, or oily solutions) and the like. Suitable excipients are, in particular, fillers such as sugars, including lactose, glucose, sucrose, mannitol, or sorbitol; cellulose preparations, for example, corn starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose (CMC), and/or polyvinylpyrrolidone (PVP: povidone); oily excipients, including vegetable and animal oils, such as sunflower oil, olive oil, or codliver oil. The oral dosage formulations may also contain disintegrating agents, such as the cross-linked polyvinylpyrrolidone, agar, or alginic acid, or a salt thereof such as sodium alginate; a lubricant, such as talc or magnesium stearate; a plasticizer, such as glycerol or sorbitol; a sweetening such as sucrose, fructose, lactose, or aspartame; a natural or artificial flavoring agent, such as peppermint, oil of wintergreen, or cherry flavoring; or dye-stuffs or pigments, which may be used for identification or characterization of different doses or combinations. Also provided are dragee cores with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain, for example, gum arabic, talc, poly-vinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
Pharmaceutical preparations that can be used orally include push-fit capsules made of gelatin (“gelcaps”), as well as soft, sealed capsules made of gelatin, and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compound may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
In some embodiments, injection (parenteral administration) may be used, e.g., intramuscular, intravenous, intraperitoneal, and/or subcutaneous. Compound I and compositions thereof for injection may be formulated in sterile liquid solutions, preferably in physiologically compatible buffers or solutions, such as saline solution, Hank's solution, or Ringer's solution. Dispersions may also be prepared in non-aqueous solutions, such as glycerol, propylene glycol, ethanol, liquid polyethylene glycols, triacetin, and vegetable oils. Solutions may also contain a preservative, such as methylparaben, propylparaben, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In addition, Compound I or compositions thereof may be formulated in solid form, including, for example, lyophilized forms, and redissolved or suspended prior to use.
In some embodiments, transmucosal, topical or transdermal administration may be used. In such formulations of Compound I, penetrants appropriate to the barrier to be permeated are used. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, bile salts and fusidic acid derivatives. In addition, detergents may be used to facilitate permeation. Transmucosal administration, for example, may be through nasal sprays or suppositories (rectal or vaginal). Compositions of Compound I for topical administration may be formulated as oils, creams, lotions, ointments, and the like by choice of appropriate carriers known in the art. Suitable carriers include vegetable or mineral oils, white petrolatum (white soft paraffin), branched chain fats or oils, animal fats and high molecular weight alcohol (greater than C12). In some embodiments, carriers are selected such that the active ingredient is soluble. Emulsifiers, stabilizers, humectants and antioxidants may also be included as well as agents imparting color or fragrance, if desired. Creams for topical application are preferably formulated from a mixture of mineral oil, self-emulsifying beeswax and water in which mixture the active ingredient, dissolved in a small amount of solvent (e.g., an oil), is admixed. Additionally, administration by transdermal means may comprise a transdermal patch or dressing such as a bandage impregnated with an active ingredient and optionally one or more carriers or diluents known in the art. To be administered in the form of a transdermal delivery system, the dosage administration will be continuous rather than intermittent throughout the dosage regimen.
In some embodiments, Compound I or compositions thereof are administered as inhalants. Compound I or compositions thereof may be formulated as dry powder or a suitable solution, suspension, or aerosol. Powders and solutions may be formulated with suitable additives known in the art. For example, powders may include a suitable powder base such as lactose or starch, and solutions may comprise propylene glycol, sterile water, ethanol, sodium chloride and other additives, such as acid, alkali and buffer salts. Such solutions or suspensions may be administered by inhaling via spray, pump, atomizer, or nebulizer, and the like. Compound. I or compositions thereof may also be used in combination with other inhaled therapies, for example corticosteroids such as fluticasone proprionate, beclomethasone dipropionate, triamcinolone acetonide, budesonide, and mometasone furoate; beta agonists such as albuterol, salmeterol, and formoterol; anticholinergic agents such as ipratroprium bromide or tiotropium; vasodilators such as treprostinal and iloprost; enzymes such as DNAase; therapeutic proteins; immunoglobulin antibodies; an oligonucleotide, such as single or double stranded DNA or RNA, siRNA; antibiotics such as tobramycin; muscarinic receptor antagonists; leukotriene antagonists; cytokine antagonists; protease inhibitors; cromolyn sodium; nedocril sodium; and sodium cromoglycate.
The amounts of Compound I or compositions thereof to be administered can be determined by standard procedures taking into account factors such as the compound activity (in vitro, e.g. the compound IC50 vs. target, or in vivo activity in animal efficacy models), pharmacokinetic results in animal models (e.g. biological half-life or bioavailability), the age, size, and weight of the subject, and the disorder associated with the subject. The importance of these and other factors are well known to those of ordinary skill in the art. Generally, a dose will be in the range of about 0.01 to 50 mg/kg, also about 0.1 to 20 mg/kg of the subject being treated. Multiple doses may be used.
Compound I or compositions thereof may also be used in combination with other therapies for treating the same disease. Such combination use includes administration of Compound I and one or more other therapeutics at different times, or co-administration of Compound I and one or more other therapies. In some embodiments, dosage may be modified for Compound I or other therapeutics used in combination, e.g., reduction in the amount dosed relative to a compound or therapy used alone, by methods well known to those of ordinary skill in the art.
It is understood that use in combination includes use with other therapies, drugs, medical procedures etc., where the other therapy or procedure may be administered at different times (e.g. within a short time, such as within hours (e.g. 1, 2, 3, 4-24 hours), or within a longer time (e.g. 1-2 days, 2-4 days, 4-7 days, 1-4 weeks)) than Compound I or compositions thereof, or at the same time as Compound I or compositions thereof. Use in combination also includes use with a therapy or medical procedure that is administered once or infrequently, such as surgery, along with Compound I or compositions thereof administered within a short time or longer time before or after the other therapy or procedure. In some embodiments, the present invention provides for delivery of Compound I or compositions thereof and one or more other drug therapeutics delivered by a different route of administration or by the same route of administration. The use in combination for any route of administration includes delivery of Compound I or compositions thereof and one or more other drug therapeutics delivered by the same route of administration together in any formulation, including formulations where the two compounds are chemically linked in such a way that they maintain their therapeutic activity when administered. In one aspect, the other drug therapy may be co-administered with Compound I or compositions thereof. Use in combination by co-administration includes administration of co-formulations or formulations of chemically joined compounds, or administration of two or more compounds in separate formulations within a short time of each other (e.g. within an hour, 2 hours, 3 hours, up to 24 hours), administered by the same or different routes. Co-administration of separate formulations includes co-administration by delivery via one device, for example the same inhalant device, the same syringe, etc., or administration from separate devices within a short time of each other. Co-formulations of Compound I and one or more additional drug therapies delivered by the same route includes preparation of the materials together such that they can be administered by one device, including the separate compounds combined in one formulation, or compounds that are modified such that they are chemically joined, yet still maintain their biological activity. Such chemically joined compounds may have a linkage that is substantially maintained in vivo, or the linkage may break down in vivo, separating the two active components.
EXAMPLES
Examples related to the present invention are described below. In most cases, alternative techniques can be used. The examples are intended to be illustrative and are not limiting or restrictive to the scope of the invention.
Example 1
This example describes the formation of a solid molecular complex comprising Compound I and HPMC-AS.
Propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and HPMC-AS in a ratio of 3:7 (30% compound and 70% polymer) were dissolved in dimethylacetamide (DMA). The resulting solution was then added with stirring to very cold dilute hydrochloric acid resulting in the co-precipitation of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and HPMC-AS as a solid molecular complex wherein propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide was present in a nanoparticulate size range. The ratio of DMA to acid was in the range of 1:5 to 1:10. The co-precipitate was then washed with water to remove DMA, filtered, dried to <2% moisture content and passed through a #30 mesh screen prior to evaluation. The resulting solid molecular complex was 30% by weight propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and 70% by weight HPMC-AS.
The properties of the resulting solid molecular complex were as follows.














Property
Measure









X-ray pattern
Amorphous



Tg (range C.)
100-120



Drug loading (% w/w)
 30



Bulk Density (g./cm3)
0.15-0.45



Absolute Density (g/cm3)
  1-1.5



Specific Surface Area (cm2/g)
 3-10



Intrinsic particle size (nm)
150



Moisture Content
  <2%



DMA Content
<0.2%










Examples 2 to 7
Solid molecular complexes comprising Compound I and HPMC-AS were prepared using methods analogous to that used in Example 1 to produce solid molecular complexes wherein the ratio of the amount by weight of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide within the solid molecular complex to the amount by weight of the ionic polymer therein is 3:7, 5:5, 5:5, 4:6, 4:6, and 2:8, respectively.
The solid molecular complexes produced in Examples 1 to 7 were evaluated for amorphous nature by powder XRD. The samples were exposed under OPEN conditions by placing the sample in a bottle in the stability chamber without a lid or closure or cap on the at 40° C. and 75% relative humidity (RH) and the properties of the solid molecular complexes following such exposure were observed. The exposure periods are shown in the table below. At the end of the exposure period, a sample of the powder was taken from the bottle and placed in powder X-ray diffraction (XRD) chamber and diffraction pattern obtained. The samples were deemed stable if the powder XRD profile did not show crystalline peaks. The prepared and stored samples were also evaluated by polarized light microscopy. The incidence of polarized light results in a birefringence phenomenon, if crystals are present in the sample. For an amorphous sample, such a test could indicate presence of crystal material which indicates that amorphous material is unstable.







TABLE 1







Evaluation of drug-HPMC-AS solid molecular complexes


at varying ratios













Results after open



Drug:Polymer
Lot number
exposure at


Ex.
ratio
ZG-37427-xxx
40° C./75% RH





1
3:7
−183
STABLE after storage for up to





3 months


2
3:7
−194
STABLE after storage for up to





3 months


3
5:5
−175
UNSTABLE due to very small





crystal peaks after storage for





3 weeks


4
5:5
−185
UNSTABLE due to crystal peaks





after 2 months


5
4:6
−154
STABLE after 3 weeks of storage





No apparent birefringence





by microscopy


6
4:6
−178
STABLE after storage for up to





2 months


7
2:8
−199
STABLE after storage for 1 month









Example 8
This example describes the formation of a solid molecular complex comprising propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and EUDRAGIT® L 100. Eudragit L 100 is another anionic polymer, a polymethyl methacrylate ester with methacrylic acid as a functional group and dissolves at pH 6.0 and above.
Propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and EUDRAGIT® L 100 in a ratio of 3:7 (30% compound and 70% polymer) were dissolved in dimethylacetamide (DMA). The resulting solution was then added with stirring to very cold dilute hydrochloric acid resulting in the co-precipitation of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and Eudragit L 100 as a solid molecular complex wherein the drug was present in a nanoparticulate size range. The co-precipitate was then washed with water to remove DMA, filtered, dried, and milled to a fine powder. The ratio of DMA to acid was in the range of 1:5 to 1:10. The co-precipitate was then washed with water to remove DMA, filtered, dried to <2% moisture content and passed through a #30 mesh screen prior to evaluation. The resulting solid molecular complex was 30% by weight propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and 70% by weight Eudragit L 100.
The solid molecular complex samples were evaluated for amorphous nature right after preparation by powder XRD. The samples were the subjected to storage under OPEN conditions at 40 C/75% RH for varying periods of time similar to that shown in Examples 1-7. At the end of the exposure period, a sample of the powder was taken from the bottle and placed in powder X-ray diffraction (XRD) chamber and diffraction pattern obtained. The samples were deemed stable if the powder XRD profile did not show crystalline peaks. The prepared and stored samples were also evaluated by polarized light microscopy. The incidence of polarized light results in a birefringence phenomenon, if crystals are present in the sample. For an amorphous sample, such a test could indicate presence of crystal material which indicates that amorphous material is unstable. Results for this Example are shown in Table 2 below.
Example 9
This example was performed with all the same steps as Example 8, with the exception that propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and EUDRAGIT® L 100 were dissolved in dimethylacetamide (DMA) in a ratio of 4:6 (40% compound and 60% polymer) instead of 3:7 as in Example 8. Results for this Example are shown in Table 2 below.
Example 10
Solid molecular complexes containing the propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and Eudragit L 100-55 in ratios of 4:6 and 5:5, respectively, were formed using the microprecipitation process same as that in Example 1. Eudragit L 100-55 is similar to L 100 except that it dissolves at pH 5.5 and above and therefore more closely resembles HPMC-AS in its pH solubility profile. The prepared and stored samples were evaluated by powder XRD. Results for this Example are shown in Table 2 below.
Example 11
This example describes the formation of a solid molecular complex comprising the propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and hydroxypropylmethylcellulose phthalate (HPMCP), another anionic polymer used for enteric purposes. HPMCP is a cellulose polymer in which some of the hydroxyl groups are replaced with phthalyl esters from 27-35%. It starts dissolving at pH 5.5 and higher. Solid molecular complexes containing propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and HPMCP in 1:1 ratio were prepared using same process as that used in Example 1. The prepared and stored samples were evaluated by XRD. Results for this Example are shown in Table 2 below.







TABLE 2







Evaluation of drug-polymer solid molecular complexes at varying ratios















Drug

Storage under open




Lot #
Polymer

conditions at


Ex.
Polymer
ZG-37427-xxx
Ratio
Initial
40 C./75% RH















8
Eudragit L100
−192
3:7
Amorphous,
STABLE for up to 3






STABLE
months


9
Eudragit L 100
−155
4:6
Amorphous,
UNSTABLE;






STABLE
birefringence observed







in polarized light







microscopy after 3







weeks


10
Eudragit L100-55
−170
5:5
Amorphous,
UNSTABLE, crystal






STABLE
peaks seen after 3







weeks


11
HPMCP
−187
5:5
Crystalline,






UNSTABLE









Based on Examples 1-11, the propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide-polymer ratio of 4:6 was the highest drug loading (40%) sustainable upon storage with HPMC-AS as polymer. Therefore, this ratio was chosen for comparison with other polymers in a separate study.
Examples 12-16 were prepared by a microprecipitation process similar to that for Example 1. The dried powder samples were evaluated for amorphous nature right after preparation by powder XRD. The samples were further subjected to storage under OPEN conditions at 40 C/75% RH for varying periods of time similar to that shown in Examples 1-7. The results are shown in Table 3 below.
Example 12
Solid molecular complexes containing propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and HPMC-AS in ratio of 4:6 were found to be amorphous right after preparation (Table 3) and subject to storage for 4 weeks at 40 C/75% RH.
The XRD of the solid molecular complexes were evaluated.
Example 13
Solid molecular complexes containing propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and HPMCP in ratio of 4:6 were found to be amorphous right after preparation (Table 3) and subject to storage for 4 weeks at 40 C/75% RH.
Example 14
Solid molecular complexes containing propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and Eudragit L 100-55 in 4:6 ratio was found to be amorphous right after preparation (Table 3) and subject to storage for 4 weeks at 40 C/75% RH.
Example 15
Solid molecular complexes containing propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and polyvinylacetate phthalate (PVAP) in 4:6 ratio was crystalline right after preparation and therefore not subject to further testing. PVAP is an anionic enteric polymer formed as the phthalate ester of polyvinylacetate and contains 55-62% of phthalyl groups. It has a low Tg of 42.5 C which renders it unsuitable as a stabilizing polymer matrix. It dissolves at pH>5.
Example 16
Solid molecular complexes containing propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and cellulose acetate phthalate (CAP) in ratio of 4:6 was crystalline right after preparation and therefore not subject to further testing.
The powder XRD profiles of Examples 12-16 at the initial stage right after preparation are shown in Table 3.







TABLE 3







Evaluation of drug-polymer solid molecular complexes


at fixed ratio of 4:6 (40% drug and 60% polymer):












Lot #



Ex.
Polymer
ZG-39422-xxx
Initial XRD





12
HPMC-AS, LF
−129A
STABLE Amorphous


13
HPMCP
−129B
STABLE Amorphous


14
Eudragit L100-55
−129C
STABLE Amorphous


15
PVAP
−129D
UNSTABLE Crystalline


16
CAP
−129E
UNSTABLE Crystalline









After 1 week, the sample prepared under Example 13 showed a small peak in powder XRD indicating conversion to crystalline form. This peak became more pronounced after 2 weeks of storage.
Example 17
Samples prepared in Examples 12 and 14 did not indicate any crystalline peak in powder XRD profiles up to the end of 4 weeks of storage.
In order to further differentiate the samples from Examples 12 and 14, the samples were subject to dissolution test by placing an amount of solid molecular complex equivalent to 80 mg of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide in 900 mL of pH 6.8 phosphate buffer medium containing 0.09% HTAB surfactant in USP Paddle dissolution apparatus at a speed of 75 rpm.
In one set of experiments, a sieve cut of granules of Examples 12 and 14 were obtained by separating the #25/40 mesh sieve size fraction and subjecting to dissolution test. The HPMC-AS solid molecular complexes had increased amounts with respect to % dissolved as compared to Eudragit L 100-55 solid molecular complexes, with the HPMC-AS solid molecular complexes being about 85% dissolved at 200 minutes and with the Eudragit L 100-55 solid molecular complexes being about 40% dissolved at 200 minutes.
In another experiment, the solid molecular complex samples from Examples 12 and 14 were pre-wetted with vehicle containing hydroxypropyl cellulose (Klucel) for improved dispersion and subjected to dissolution test. The HPMC-AS solid molecular complexes had increased amounts with respect to % dissolved as compared to Eudragit L 100-55 solid molecular complexes, with the HPMC-AS solid molecular complexes being about 60-65% dissolved at 200 minutes and with the Eudragit L 100-55 solid molecular complexes being about 20-25% dissolved at 200 minutes.
Based on results from these experiments, the HPMC-AS was a superior polymer in stabilizing the drug upon storage under stress conditions but also enabling drug release and maintaining supersaturation of amorphous drug during dissolution without reverting to crystalline form within the period of testing. The Eudragit L 100-55 did not enhance drug release as compared to HPMC-AS and therefore is not expected to provide the exposure and bioavailability as well as HPMC-AS. At the end of 3 h, almost 90% drug was released from Example 12 (HPMC-AS) while Example 14 (Eudragit L-100-55) had only about 50% drug released. Thus, a propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide and HPMC-AS solid molecular complex made by the microprecipitation process therefore not only stabilizes the amorphous compound for handling and storage but also ensures rapid drug release resulting in superior dissolution and therefore bioavailability.
Example 18
This Example demonstrates the stabilization of solid molecular complexes in aqueous systems. The solid molecular complex of drug-HPMC-AS is suspended in an aqueous vehicle containing 2% hydroxypropylcellulose (Klucel LF). Upon addition of >0.5% w/w colloidal silicon dioxide, the resulting suspension was found to be stable for up to 8 h under normal conditions and for up to 24 h under refrigerated conditions.
Example 19
Propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide can exist in polymorphic forms, for example as polymorphic forms 1 or 2, where such polymorphic forms may be isolated as the substantially pure polymorph. The desired polymorphic form may be prepared, for example, by using appropriate crystallization conditions. For example, Form 1 was isolated by recrystallization from acetone/absolute ethanol (e.g. 1:1 to 5:1, preferably 2:1 by volume) as explained in detail herein. Form 2 can be formed for example directly via crystallization from dimethylacetamide/methanol or under a variety of recrystallization conditions, for example, is formed by recrystallization from methyl-t-butyl ether/tetrahydrofuran, ethyl acetate, acetone, or is formed by heating/melting and re-solidifying any solid form, such as polymorph Form 1, or a mixture of solid forms. The substantially pure isolated polymorphic forms were characterized by X-Ray Powder Diffraction (XRPD), differential scanning calorimetry (DSC) and infrared spectroscopy (See Example 20 below).
To demonstrate the formation of polymorphic Form 1, propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide (7.8 kg) was treated with acetone:absolute ethanol (1:4 by volume, 19 kg) in a reactor and agitated at 20° C.±5° C. for at least 6 hours. The contents were filtered and the solids were washed with acetone:absolute ethanol (1:4 by volume) mixture. Solids were treated with tetrahydrofuran (26.6 kg), and the suspension was heated to 60° C.±5° C. for at least 30 minutes and agitated. The mixture was cooled to 55° C.±5° C. and methyl-t-butyl ether (92.3 kg) was added. The resulting suspension was cooled to 20° C.±5° C. for at least 1 hour. The contents were filtered and the solids were washed with methyl-t-butyl ether and dried. The solid was treated with acetone:absolute ethanol (2:1 by volume) in a reactor. The contents were agitated and the suspension was heated at 60° C. until a solution was achieved. The solution was filtered through a large polish filter to remove any residual solid from the methyl-t-butyl ether treatment step. The filtrate was concentrated under vacuum, stirred at 20° C. ±5° C. for at least 30 minutes and filtered. The solids were washed with pre-cooled (0° C. to −5° C.) ethanol and dried at 45° C. followed by drying at 75° C. under vacuum until a constant weight was achieved, to provide pure propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide polymorphic Form 1. Form 1 was also prepared treating a sample with 120 mL of acetone:ethanol (1:1 by volume) at refluxing, then filtering hot and removing solvent from the filtrate under vacuum until solid precipitates out.
Example 20
The propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide polymorphic Form 1 and Form 2 were characterized by X-ray powder diffraction, infra-red spectrometry, and differential scanning calorimetry. Samples were analyzed by X-ray powder diffraction (XRPD) using a ShimadzuXRD-6000 X-ray powder diffractometer using Cu Kα radiation. The tube voltage and amperage were set to 40 kV and 40 mA, respectively. The divergence and scattering slits were set at 1° and the receiving slit was set at 0.15 mm. Diffracted radiation was detected by a NaI scintillation detector. A θ-2θ continuous scan at 3°/min (0.4 sec/0.02° step) from 2.5° to 40° 2θ was used. A silicon standard was analyzed to check the instrument alignment. Data were collected and analyzed using XRD-6100/7000 v.5.0. Sample was prepared for analysis by placing it in an aluminum holder with silicon insert. The results are provided in FIG. 1 (Form 1) and FIG. 2 (Form 2) and the following Table 4.







TABLE 4







XRPD 2θ values for P-0001 polymorphic Form 1 and Form 2.


2θ value (+/−0.2)










Form 1
Form 2














4.7





6.7




8.8



9.4
9.2



10.0



11.0



12.5




13.5



14.2
14.1




14.5



14.9
15.0



15.4



16.1
16.2




17.0



17.3
17.7



18.6
18.3



19.0
19.1




19.7




20.6



20.0
20.9



21.2
21.4



21.6
22.0



22.2
22.2




23.2



23.9
23.8




24.1




24.4




25.1




25.7



6.1
26.6



6.8
28.1




28.8



9.2
29.3




30.1




31.1




31.7




34.5




34.9




35.9




39.2




41.3










The propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide polymorphic Form 1 and Form 2 were further analyzed by infra-red spectrometry. Table 5 provides the characteristic wavenumbers observed for each sample.







TABLE 5







IR absorption spectrum wavenumber values for


P-0001 polymorphic Form 1 and Form 2.


Wavenumber cm−1










Form 1
Form 2














3238
3266




3121




2969



2879
2880



1709



1645
1639



1590
1589



1519
1519



1485
1487



1417
1417



1331
1322



1305
1306



1280
1287



1246
1246



1211
1215



1149
1143



1102
1096



1022
1027



1013
1012



965
968



915
916



891
893




857



825
825



796
798



773
767



717



685
683



651
662



631




607



587
585



564
558



550



532
532



516
508



503










The propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide polymorphic Form 1 and Form 2 were also analyzed by differential scanning calorimetry (DSC), scanning at 10.00° C. per minute. The DSC thermogram for Form 1 shows an exothermic shift at approximately 152-164° C. and an endothermic peak at 268.0° C. The DSC thermogram for Form 2 shows an endothermic peak at 271.2° C.
Example 21
Propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide is characterized as having functionalities providing both weakly basic and weakly acidic centers which can form organic salt complexes, resulting in improved solubility. For example, the N-7 of the azaindole portion is weakly basic (pKa approximately 4-5) and can form an acid addition salt complex with an organic acid such as benzenesulfonic acid, methylsulfonic acid or toluenesulfonic acid, preferably methanesulfonic acid or toluenesulfonic acid. Such mesylate or tosylate salts provide advantage over the free base, such as an improved solubility, improved intrinsic dissolution rate, and lower melting point than the free base. The improved intrinsic dissolution rate provides an advantage in formulation of the salt, for example, formulation in an amorphous form by methods described in the above examples. The improved solubility provides more efficient and cost effective formulation, for example spray drying or microprecipitated bulk processing can be performed using far less solvent volumes due to the intrinsic solubility. Such advantages may also be provided by formation of the mesylate or tosylate salt in situ during the processing, for example the process of spray drying, solvent controlled precipitation, or pH controlled precipitation. Also, lowered melting of the salt forms provides a more efficient hot melt extrusion process, allowing for the melt to proceed at lower temperatures.
Acid addition salts, including sulfonic acid series of organic anions such as tosylate, besylate or mesylate, of Propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide are preferably formed using acetone, which provides solubility of the free base and is a non-solvent once the salt is formed. Typically, Propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide is added to 20-50 solvent volumes of acetone with stirring and heating (30-35° C.), followed by the addition of 1 equivalent of the desired acid counter ion. The solution is slowly cooled to 2-8° C. and the solid is isolated by either filtration or centrifugation, followed by vacuum drying. The resulting solid may be amorphous, partially amorphous or crystalline, and can be recrystallized as needed from alcohol:acetone:ethyl acetate or alcohol alone to obtain the desired solid in crystalline form.
The mesylate salt of propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide was prepared by suspending 5 g (9.7 mmol) of polymorph Form 2 in 100 mL of acetone, mixing with heating 30-35° C. Methanesulfonic acid (0.63 mL, 9.7 mmol) was added and the solution cooled to 5° C. over 30 minutes. The resulting solid was isolated by filtration, washed and dried under vacuum to provide the desired salt. The tosylate salt was prepared similarly. Exemplary XRPD patterns for the mesylate and tosylate salts are provided in FIGS. 3 and 4, respectively, as compared to the free base polymorph Form 2. The DSC thermogram for the mesylate salt shows an endothermic peak at approximately 231° C. The DSC thermogram for the tosylate salt shows an endothermic peak at approximately 223° C. and another at approximately 253° C.
The resulting salts are processed through the techniques discussed in the above examples, such as spray drying, solvent controlled precipitation, pH controlled precipitation, or hot melt extrusion to provide the preferred amorphous form, or further processed with suitable excipient materials to provide for a directly compressible or encapsulated dosage form. The salt forms have advantages in such processes, such as to minimize solvent utilization, increase yield, purity and throughput, as well as achieve constructs not attainable using conventional solvent techniques.
Example 22
This example describes the preparation of a solid dispersion (MBP) of amorphous Compound I in HPMCAS
Preparation of the DMA Phase:
The concentration of Compound I and HPMCAS in the organic solvent was 35% (w/w), while the ratio of Compound I and HPMCAS is 30 to 70: The temperature of the solution was adjusted to 70° C.
In a 250 ml double jacketed glass flask reactor 21 g of Compound I were dissolved in 130 g Dimethylacetamide (DMA) at 20-25° C. Under stirring. 48.9 g of HPMC-AS were added to the solution. The mixture was heated up to 70° C. A clear solution was obtained.
Preparation of the Aqueous Phase
In a double jacketed 2.0 liter reactor such as illustrated in FIG. 5, 1210 g of 0.01 N HCl was tempered to 5° C. Out of the bottom valve of the reactor the water phase was circulated by the high shear mixer or with an auxiliary pump, preferred a rotary lobe pump, and then followed by the high shear mixer, back to the top of the reactor. The inlet of the recirculation into the reactor was under the fluid level in order to prevent foaming (see FIG. 5).
Precipitation
High Shear Mixer (HSM)
The tip speed of the rotor in the high shear mixer was set 25 m/sec. A rotor/stator combination with one teeth row, each for rotor and stator was used.
Dosing of the DMA solution
The DMA solution tempered at 70° C. was dosed with a gear pump via an injector nozzle, which was pointing into the mixing chamber of the high shear mixer, into the circulating aqueous phase.
Dosing Rate of the DMA Solution
The DMA solution was dosed into the aqueous phase resulting in a ratio of HCl/DMA, in the mixing chamber of the high shear mixer of 100/1.
Additional Dispersing in the HSM (after Precipitation), Isolation and Washing
After addition of the DMA solution the obtained MBP suspension was dispersed for an additional time, corresponding to equivalents of the batch passing the high shear mixer. The time was corresponding to a turnover in calculated recirculation times of the batch of 6 times.
The obtained suspension, held at 5-10° C. was separated from the solid MBP. This was done by using a suction filter. The isolated MBP was washed with 0.01 N HCl (15 kg 0.01 N HO/kg MBP) followed by washing with water (5 kg water/kg MBP) in order to remove the DMA. The isolated (wet) MBP had a water content between 60 and 70%.
Delumping and Drying
Prior to drying the (wet) MBP was delumped by using a sieve mill. The (wet) MBP was dried in a cabinet dryer. During the drying process of the MBP the temperature of the product was below 40° C. in order to avoid recrystallization of the API. The pressure inside the cabinet dryer was below 20 mbar. The water content of the MBP after drying was below 2.0% and was signed amorphous in the XRPD pattern.
Example 23
This example describes the spray dry formation of a solid molecular complex comprising Compound I and HPMC-AS.
Compound I is prepared with a polymer such as HPMCAS, optionally including a surfactant (e.g. an ionic surfactant such as sodium, 1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-sulfonate (Docusate Sodium) or a nonionic surfactant such as Polysorbate 80). In general, a suitable solvent system, such as 20:80 (w/w) tetrahydrofuran:acetone is equilibrated to 30° C., and Compound I is added to a level of 2-10% solids in 4-6 portions with stirring. HPMCAS at a suitable ratio, for example 70:30 w/w HPMCAS:Compound I, is added (alternatively HPMCAS and surfactant at for example 65:5:30 HPMCAS:surfactant:Compound I) is added. The temperature is raised to 35-40° C., and the system optionally filtered to ensure removal of any unsolubilized solids. The solution is then spray dried to provide spherical particles with a size distribution of 1-20 microns. Further processing may include drying of the material in a fluid bed or tray dryer, and the resulting material may be densified, for example, by roller compaction. As an example, Compound I and HPMCAS in a ratio 30:70 (w/w) were dissolved to a level of 5.4% solids in a blend of 20:80 (w/w) tetrahydrofuran and acetone. The resulting solution was then spray dried to produce a solid dispersion, amorphous powder. The solution was spray dried using a suitable spray dryer, e.g., a GEA-Niro SDMICROTM Spray Dryer for smaller batches (e.g. 10 gm solids) and a Niro Mobile Manor Spray Dryer for larger batches (e.g. 1 kg solids). For example, for a 10 gm batch, 35.0 gm of tetrahydrofuran was blended with 140.0 gm of acetone in a glass beaker, and 3.0 gm of Compound I was added with stirring for 10 minutes to dissolve; 7.0 gm of HPMCAS-L (Shin-Etsu grade NF) was then added and stirred. While the solids appeared to be dissolved, the solution was filtered through filter paper prior to spray drying. The solution was spray dried with the GEA-Niro SDMICROTM Spray Dryer with inlet/outlet conditions of 85° C. and 55° C., respectively, with atomization gas pressure at 0.5 bar. The spray dried material was collected in the cyclone collector, 5.78 gm or 58% yield.
A 1.6 kg batch was also prepared, where the solution was prepared similarly, only instead of filtering, the solution was stirred overnight at room temperature to ensure all solids were dissolved. A 200 mesh screen was attached to the end of the feed hose to remove any un-dissolved particles and the solution was spray dried using the Mobile Manor Spray Dryer. The inlet/outlet conditions were 100° C. and 55° C., respectively, with atomization gas pressure at 1.0 bar, with gas flow rate of 90 kg/hr. The material was spray dried over two days, and material collected after the first day was subjected to vacuum drying at 45° C. to remove residual solvents. The collected material was assessed for bulk density (0.23 gm/mL), particle size (8 microns with a normal distribution and standard deviation of 3 microns), residual solvent (after 89 hours of vacuum drying, the large batch had residual solvents of 0.001% acetone and 0.017% tetrahydrofuran), polarized light microscopy, DSC (the DSC thermogram for the small batch shows an endothermic peak at approximately 243° C., while the thermogram for the large batch showed essentially no peak) and XRPD (which showed an amorphous material).
All patents and other references cited in the specification are indicative of the level of skill of those skilled in the art to which the invention pertains, and are incorporated by reference in their entireties, including any tables and figures, to the same extent as if each reference had been incorporated by reference in its entirety individually.
One skilled in the art would readily appreciate that the present invention is well adapted to obtain the ends and advantages mentioned, as well as those inherent therein. The methods, variances, and compositions described herein as presently representative of preferred embodiments are exemplary and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art, which are encompassed within the spirit of the invention, are defined by the scope of the claims.
It will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention. For example, variations can be made to crystallization or co-crystallization conditions for Ret and Ret surrogate proteins and/or various kinase domain sequences can be used. Thus, such additional embodiments are within the scope of the present invention and the following claims.
The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein. Thus, for example, in each instance herein any of the terms “comprising”, “consisting essentially of” and “consisting of” may be replaced with either of the other two terms. Thus, for an embodiment of the invention using one of the terms, the invention also includes another embodiment wherein one of these terms is replaced with another of these terms. In each embodiment, the terms have their established meaning. Thus, for example, one embodiment may encompass a method “comprising” a series of steps, another embodiment would encompass a method “consisting essentially of” the same steps, and a third embodiment would encompass a method “consisting of” the same steps. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims.
In addition, where features or aspects of the invention are described in terms of Markush groups or other grouping of alternatives, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group or other group.
Also, unless indicated to the contrary, where various numerical values are provided for embodiments, additional embodiments are described by taking any 2 different values as the endpoints of a range. Such ranges are also within the scope of the described invention.
Thus, additional embodiments are within the scope of the invention and within the following claims.

## Claims

1. A solid dispersion comprising Compound I having the formula:




wherein Compound I is molecularly dispersed within a polymer matrix formed by hydroxypropylmethyl cellulose acetate succinate (HPMCAS) in its solid state, and wherein Compound I is substantially amorphous.

2. The solid dispersion according to claim 1, wherein Compound I is present in a nanoparticulate size range.

3. The solid dispersion according to claim 1, wherein Compound I is present in the solid dispersion in an amount of from about 20% to about 60% by weight of the solid dispersion.

4. The solid dispersion according to claim 1, wherein Compound I is present in the solid dispersion in an amount of from about 20% to about 40% by weight of the solid dispersion.

5. The solid dispersion according to claim 1, wherein at least 98% of Compound I is in amorphous form.

6. The solid dispersion according to claim 1, wherein the ratio of an amount by weight of Compound I within the solid dispersion to an amount by weight of HPMCAS is from about 1:9 to about 1:1.

7. The solid dispersion according to claim 1, wherein the ratio of an amount by weight of Compound I within the solid dispersion to an amount by weight of HPMCAS is from about 2:8 to about 4:6.

8. The solid dispersion according to claim 1, wherein the ratio of an amount by weight of Compound I within the solid dispersion to an amount by weight of HPMCAS is about 3:7.

9. The solid dispersion according to claim 1, wherein HPMCAS is selected from the group consisting of AS-LF, AS-MF, AS-HF, AS-LG, AS-MG, and AS-HG.

10. The solid dispersion according to claim 1, wherein HPMCAS is present in an amount of not less than about 20% by weight of the solid dispersion.

11. The solid dispersion according to claim 1, HPMCAS is present in an amount greater than about 50% by weight of the solid dispersion.

12. The solid dispersion according to claim 1, wherein HPMCAS is present in an amount of about 20% to about 70% by weight of the solid dispersion.

13. A formulation comprising the solid dispersion according to claim 5.

14. The formulation according to claim 13, wherein the formulation is a tablet.

15. The formulation according to claim 13, wherein the formulation is a coated tablet.

16. The formulation according to claim 15, further comprising colloidal silicon dioxide.

17. The formulation according to claim 16, wherein the colloidal silicon dioxide is present in an amount of at least 0.5% by weight of the formulation.

18. The formulation according to claim 15, further comprising 2% by weight hydroxypropylcellulose.

19. A composition comprising a solid dispersion according to claim 5 and a pharmaceutically-acceptable carrier.

20. A tablet comprising a solid dispersion, wherein the solid dispersion comprises Compound I having the formula:



wherein Compound I is molecularly dispersed within a polymer matrix formed by hydroxypropylmethyl cellulose acetate succinate (HPMCAS) in its solid state, Compound I is substantially amorphous, and the ratio of an amount by weight of Compound I within the solid dispersion to an amount by weight of HPMCAS is about 3:7.

21. The tablet according to claim 20, wherein the tablet is coated.

22. The tablet according to claim 21, wherein Compound I is stable.

23. The tablet according to claim 22, wherein Compound I is stable for at least 2 months at 40° C. and 75% relative humidity.

24. The tablet according to claim 23, wherein Compound I is stable for at least 3 months at 40° C. and 75% relative humidity.

25. The tablet according to claim 23 or 24, wherein the compound is stable if at least 95% remains in amorphous form at the end of the time period.

26. The tablet according to claim 23 or 24, wherein the compound is stable if at least 98% remains in amorphous form at the end of the time period.

27. The tablet according to claim 23 or 24, wherein the stability of compound I is evaluated using powder X-ray diffraction.

28. The tablet according to claim 27, wherein Compound I is stable if it does not form any detectable crystalline peaks.

29. The tablet according to claim 22, 23, or 24, wherein compound I stability is evaluated using dissolution testing.